


CURRICULUM VITÆ - September 2026

Mario Silva, MD, PhD

GENERAL INFORMATION

- First name: Mario
- Last name: Silva
- Born in Parma (Italy), September 24, 1983
- Married, two daughters, one son
- Work address: Scienze Radiologiche, Department of Medicine and Surgery (DiMeC)
University Hospital of Parma
via Gramsci 14, 43126, Parma, Italy
Phone: +39 0521 703431
- E-mail address: mario.silva@unipr.it



Referees

Nicola Sverzellati, MD, PhD

Professor of Radiology, Section of Diagnostic Imaging, Department of Surgical Sciences
University of Parma
Via Gramsci 14, 43100, Parma, Italy

Alexander A. Bankier, MD, PhD

Professor of Radiology, University of Massachusetts Medical School
Chief of Cardio-Thoracic Imaging, Diagnostic Radiology, UMass Memorial
55 Lake Avenue North
Worcester MA 01655

Sundeep M Nayak, MD

Senior Physician, Department of Radiology
Kaiser Permanente Northern California
San Leandro, CA, USA

GENERAL INFORMATION	1
REFEREES	1
EDUCATION	3
EDUCATION IN MEDICINE AND RADIOLOGY	3
PERSONAL INTERESTS	ERROR! BOOKMARK NOT DEFINED.
CLINICAL CAREER	3
CLINICAL EXPERTISE	3
CLINICAL CERTIFICATION	3
COMMITTEE IN CLINICAL JOB COMPETITION	ERROR! BOOKMARK NOT DEFINED.
ACADEMIC CAREER	4
FELLOWSHIPS	4
ACADEMIC POSITIONS	4
TEACHING ASSIGNMENTS	5
ACADEMIC ACTIVITY	5
AWARDS	7
SCIENTIFIC ACTIVITY	8
NATIONAL AND INTERNATIONAL SCIENTIFIC COLLABORATIONS	8
GRANTS	8
CLINICAL TRIALS	9
DEVELOPMENT OF QUANTITATIVE IMAGING AND ARTIFICIAL INTELLIGENCE	11
MEMBERSHIP OF SCIENTIFIC SOCIETIES	11
MEMBERSHIP OF INTERNATIONAL SCIENTIFIC COMMITTEES	12
INTERNATIONAL GUIDELINES COMMITTEE	12
EDITOR FOR INTERNATIONAL SCIENTIFIC JOURNALS	12
REVIEWER FOR INTERNATIONAL AUTHORITIES	13
REVIEWER FOR INTERNATIONAL SCIENTIFIC JOURNALS	13
EDITOR OF BOOK	14
AUTHOR OF BOOK CHAPTERS	14
CONGRESSES AND COURSES	32
ABSTRACT OF SCIENTIFIC POSTER PRESENTATION	32
ABSTRACT OF ORAL PRESENTATIONS	32
CONGRESSES/COURSES AS FACULTY: INVITED SPEAKER	32
CONGRESSES/COURSES AS FACULTY: MODERATOR	33
CONGRESSES/COURSES AS FACULTY: SCIENTIFIC COMMITTEE	33
ATTACHMENTS	35
ATTACHMENT 1	35

EDUCATION

Education in Medicine and Radiology

1. 2002 – 2008 Medical School, graduation 110/110 “cum laude” at University of Parma (IT);
2. 2007 – 2009 Internship in Radiology at the University of Parma (Chief Prof. M. Zompatori) (IT);
3. 2009 Medical Board exam habilitation at University of Parma (IT);
4. 2009 Medical License: Albo Provinciale dei Medici Chirurghi di PIACENZA (Ordine della Provincia di Piacenza) n. 0000002323;
5. 2010 Course of Cardiac CT for Trainees: “IV Corso Residenziale di Cardio TC per Specializzandi”. Coordinator: Cademartiri F, MD, PhD. Azienda Ospedaliero-Universitaria di Parma (IT);
6. 2011 – 2012 Trainee in Cardio-Vascular Imaging at the Diagnostic Imaging Department of Policlinico S. Orsola-Malpighi (Bologna, IT);
7. 2009 – 2014 Trainee in Diagnostic Imaging School at the University of Parma (IT), graduated in Diagnostic Imaging in July 2014.

CLINICAL CAREER

Clinical Expertise

Main expertise in Pulmonary, Cardiac, Vascular, Oncologic, and Emergency Imaging.

- 2014 – present University Hospital of Parma.
- 2014 – present Multidisciplinary Team of Thoracic Oncology at the University Hospital of Parma (weekly multidisciplinary discussion ≈ 15-30 cases/week)

Clinical Certification

- 2018-2025 Basic Life Support - Defibrillation (BLS-D) certificate according to America Heart Association (AHA - <https://www.heart.org>)
- 2018-2024 Good Clinical Practice (GCP) certificate by the NIDA Clinical Trials Network (<https://gcp.nidatrainig.org>)
- 2019-2025 Advanced Cardiovascular Life Support (ACLS) certificate according to America Heart Association (AHA - <https://www.heart.org>)
- April 2021 – October 2021 subscription and attendance at the “Master di Formazione per Direzione di UOC di Radiologia” issued by Società Italiana di Radiologia Medica (SIRM)
- September 2021 – December 2021 – “Aggiornamento formative sulle esposizioni mediche – CORSO SIRM-AIFM-AIRM D.Lgs.101/20” issued by Società Italiana di Radiologia Medica (SIRM)
- October 2021 – “Tutela della privacy in ambito sanitario” issued by Servizio Sanitario Regionale Emilia Romagna
- November 2021 – “La trasparenza nella Pubblica Amministrazione” issued by Regione Emilia Romagna

ACADEMIC CAREER

Fellowships

- 2010 – 2023 Research Fellow in lung cancer screening trial at the Multicenter Italian Lung Detection (MILD and bioMILD), Fondazione IRCCS Istituto Nazionale Tumori (INT, Milan, Italy);
- 2013 Research Fellow in Cardiothoracic Imaging at Beth Israel Deaconess Medical Center (BIDMC, Harvard Medical School, Boston, MA, USA)
- 2014 – 2018 Reading Radiologist in lung cancer screening at the MILD and bioMILD trials at Istituto Nazionale dei Tumori di Milano (*screening low-dose computed tomography read: > 10,000*).

Academic positions

- 2014-2017 – **Doctorate** in Surgical Sciences and Applied Microbiology (Date of PhD defense: March 15, 2017)
University of Parma, Department of Surgical Sciences
- 2015 – 2020 Assistant Professor [**RTD art. 24 lettera a**], legge n. 240 del 30 dicembre 2010; SC 06/I1, SSD MED/36 Diagnostic Imaging and Radiation Therapy]
University of Parma, Department of Surgical Sciences
- 2020 – 2024 **Vice President** of the Degree course in IMAGING AND RADIOTHERAPY TECHNIQUES
University of Parma, Department of Surgical Sciences
- 2021 – 2024 Assistant Professor [**RTD art. 24 lettera b**], legge n. 240 del 30 dicembre 2010; SC 06/I1, SSD MED/36 Diagnostic Imaging and Radiation Therapy]
University of Parma, Department of Surgical Sciences
- 2021 – **Adjunct Assistant Professor** at the TH Chan School of Medicine at the UMass Chan Medical School
University of Massachusetts, Department of Radiology (Worcester, MA, USA)
URL: <https://profiles.umassmed.edu/display/28136779>
- 2024 – **Associate Professor** SC 06/I1, SSD MED/36 Diagnostic Imaging and Radiation Therapy
University of Parma, Department of Surgical Sciences
- 2024 – **President** of the Degree course in IMAGING AND RADIOTHERAPY TECHNIQUES
- 2024-2027 Departmental Research Committee, Subgroup “Clinical Research”
University of Parma, Department of Surgical Sciences
- 2025 **Rappresentante dell’Assicurazione di Qualità (RAQ)** in the Degree Course of Medicine and Surgery
University of Parma, Department of Surgical Sciences
- 2025 Internal Member of the “**Comitato di Indirizzo**” for the Department of Medicine and Surgery
University of Parma, Department of Surgical Sciences

Academic Certifications

- 2018 – **Certification for Associate Professorship** issued by the National Scientific Review Board (Abilitazione Scientifica Nazionale – **ASN** – alle funzioni di Professore Universitario di **II Fascia**, valida dal 02/10/2018 al 02/10/2024 art. 16, comma 1, Legge 240/10 – Official publication at <https://asn16.cineca.it/pubblico/miur/esito-abilitato/06%252FI1/2/5>).
- 2022 – **Certification for Full Professorship** issued by the National Scientific Review Board (Abilitazione Scientifica Nazionale – **ASN** – alle funzioni di Professore Universitario di **I Fascia**, valida dal 07/06/2022 al 07/06/2032 art. 16, comma 1, Legge 240/10 – Official publication at <https://asn21.cineca.it/pubblico/miur/esito/06%252FI1/1/2>) – See “Attachment 1”.

Teaching Assignments

- 2016 – present *Chief of teaching course* and Official teaching Assignment: Operating Protocols Magnetic Resonance And Computed Tomography; Degree Course In Imaging And Radiotherapy Techniques, University Of Parma
- 2017 – present Residency Program at the University of Parma
 - Diagnostic Imaging (39 CFU-P, 2 CFU-F)
 - Respiratory Diseases (1 CFU-F)
 - Otorhinolaryngology (1 CFU-P)
- 2017 – present Official teaching Assignment: Diagnostics Of Images And Radiology; Master Degree In Medical School, University of Parma
- 2018 – present Official teaching Assignment: Diagnostics Of Images And Radiology; Master Degree In Dentist School, University of Parma
- 2022
- 2024

Academic Activity

- Students and trainees mentoring
- Responsibility of degree thesis for:
 - Master Degree in Medical School
 - Degree course in Imaging And Radiotherapy Techniques
 - Residency Program in Diagnostic Imaging
- Manager of International exchange program at the Section of Radiology, Department of Medicine and Surgery (DiMeC) at the University of Parma:
 - 2019 Visiting Professor: Sundeep M Nayak, MD, Senior Physician, The Permanente Medical Group, Inc. – San Leandro, California
- Committee member and Secretariat in Academic job competitions for research positions, including post-doc positions:
 - Role: Secretary
 - Selection: Procedura di selezione pubblica, per titoli e colloquio, indetta con decreto rettorale rep drd n. 309/2018, prot. 27097 in data 09/02/2018, per il conferimento di n. 1

assegno di ricerca di durata 24 mesi avente per argomento "Micro-tomografia computerizzata nello sviluppo dei farmaci: un metodo non invasivo per valutare la progressione di malattia", per il s.s.d. MED/36 "Diagnostica per immagini e radioterapia" presso il Dipartimento di Medicina e Chirurgia dell'Università di Parma, ai sensi dell'art. 22 della legge 240/2010

- Role: Secretary

Selection: Procedura di selezione pubblica, per titoli e colloquio, indetta con decreto rettorale rep. drd n. 462/2020 prot. 93856 del 26.05.2020, per il conferimento di n. 1 assegno di ricerca di durata 24 mesi avente per argomento "Micro-tomografia computerizzata nello sviluppo dei farmaci: un metodo non invasivo per valutare la progressione di malattia", per il s.s.d. MED/36 "Diagnostica per immagini e radioterapia" presso il Dipartimento di Medicina e Chirurgia dell'Università di Parma, ai sensi dell'art. 22 della legge 240/2010

- Role: Secretary

Selection: Bando per conferimento di contratto di diritto privato a titolo gratuito a dirigenti medici per la Scuola di Specializzazione in Radiodiagnostica dell'Università di Parma per l'anno accademico 2019/2020, ai sensi del DM. n. 68 del 4 febbraio 2015

- Invited Faculty:

- University of Padova, Italy – Host Faculty: Prof. Paolo Spagnolo
Residency Program in Pulmonology. Symposium: "Lung cancer screening and clinical management of lung nodule". December 20, 2019 – Padova (IT).
- University of Massachusetts Medical Center and University of Massachusetts Medical School, Massachusetts (USA) – Host Faculty: Prof. Max Rosen and Prof. Alexander Bankier
 - 13th Annual Edward Smith Lecture "Living through Covid -19 in Northern Italy – views from a radiologist, physician, and citizen". June 10, 2020 – Online and Worcester (MA)
 - Residency Program in Radiology "Difficulties in ILD imaging: IPF vs CHP". November 20, 2020 – Online and Worcester (MA)
- University of Piemonte Orientale, Italy – Host Faculty: Prof. Alessandro Carriero
Italian Network of Residency Program in Radiology. Symposium: "La dispnea". March 8, 2022 – Online National Streaming.
- University of Modena and Reggio Emilia, Italy – Host Faculty: Prof. Guido Ligabue
Residency Program in Radiology. Symposium: "Semeiotica del nodulo polmonare". March 13, 2023 – Modena (IT).
- University of Piemonte Orientale, Italy – Host Faculty: Prof. Alessandro Carriero
Italian Network of Residency Program in Radiology. Symposium: "Tumore polmonare: semeiotica imaging del paziente con malattia avanzata". March 15, 2023 – Online National Streaming.

- National Doctorate:

- Alma Mater Studiorum – Università di Bologna
Dottorato di Ricerca in Oncologia, Ematologia e Patologia (XXXVI Ciclo)
Title: "A machine learning approach to identify patients with resected non-small-cell lung cancer with high risk of relapse"
Candidate: Andrea PROCHOWSKI IAMURRI
Role: Reviewer (year 2023)
- Alma Mater Studiorum – Università di Bologna
Dottorato di Ricerca in Oncologia, Ematologia e Patologia (XXXVI Ciclo)
Title: "Application and development of an artificial intelligence based multiparametric malignancy index (MMI) for interpretation of 3T multiparametric prostate MRI"
Candidate: Fabio FERRONI

Role: Reviewer (year 2024)

▪ International Doctorate:

- University of Groningen, The Netherlands
Candidate: Sunyi ZHENG
Role: Opposition committee in PhD Defense (June 22, 2021)
- University of Bern, Switzerland
Candidate: Alan Arthur PETERS
Role: Scientific external referee (year 2025)

Awards

1. 2014 RSNA Introduction to Research for International Young Academics (IRIYA) Program, sponsored by the Committee on International Radiology Education (CIRE).
2. 2015 The Outstanding Young Person (TOYP) Prize in Category “Research” organized by the Junior Chamber International (JCI), Parma Section, Italy.
3. 2015 “Premio Luigi Pigorini” National award to proficient scientific production in Thoracic Imaging, for Radiologists under the age of 40 – Società Italiana di Radiologia medica (SIRM), Section of Thoracic Imaging.
4. 2017 European Congress of Radiology (ECR 2017, March 1-5 – Vienna, Austria): Best Scientific Paper Presentation Award 2017 within the topic "Chest"
Awarded presentation: “Subsolid and Part-Solid Nodules in Lung Cancer Screening: Comparison Between Visual and Computer-Aided Detection” **Silva M**, Capretti G, Sverzellati N, Jacobs J, Ciompi F, van Ginneken B, Schaefer-Prokop CM, Marchianò A, Pastorino U.
5. 2017 54th National Congress of the Italian Society of Rheumatology (SIR – November 22-25, Rimini, Italy) Awarded poster: “Quantification of Interstitial Lung Disease in Sjogren Syndrome” **Ariani A**, **Silva M**, Martin Garrido, Martin Segarra O, Santilli D, Mozzani F, Luque Pinilla JM, Sverzellati N, Guisado Vasco P.
6. 2017 Journal of Thoracic Imaging’ (JTI) Editor’s Recognition Award for Distinction in Reviewing in 2017, as noted in the January 2018 issue of the journal.
7. 2018 Journal of Thoracic Imaging’ (JTI) Editor’s Recognition Award for Distinction in Reviewing in 2018, as noted in the January 2019 issue of the journal.

SCIENTIFIC ACTIVITY

Scopus Author ID: 56335785800 <http://www.scopus.com/authid/detail.uri?authorid=56335785800>

Web of Science ResearcherID: B-9509-2016 <http://www.researcherid.com/rid/B-9509-2016>

ORCID: 0000-0002-2538-7032 <http://orcid.org/0000-0002-2538-7032>

ResearchGate: https://www.researchgate.net/profile/Mario_Silva12/

Google Scholar: http://scholar.google.it/citations?user=gzM0B_QAAAAJ&hl=en

National And International Scientific Collaborations

1. 2010 – 2023 Fondazione IRCCS Istituto Nazionale dei Tumori (INT) – Milan, Italy
2. 2014 – 2016 Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School – Boston (MA), Unites States of America
3. 2014 – 2023 Radboud University Medical Center – Nijmegen, The Netherlands
4. 2017-2019 University of Brescia – Brescia, Italy
5. 2018 – ongoing Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF), Faculty of Medicine and Health, The University of Sydney, Royal Prince Alfred Hospital – Camperdown, Australia
6. 2020 – present Institute for Diagnostic Accuracy (iDNA) awarded an EU project (4-in-the-lung-run) in the field of lung cancer screening and early diagnosis of smoking related lung disease and cardiovascular risk factors
7. 2021 – present University of Twente (The Netherlands) leading the multicenter project “Preference study for Big-3 Screening”

Grants

1. 2016 – ESTI Experienced Chest Radiology Researchers Grant – European Society of Thoracic Imaging (ESTI).
Project title: “Information From Computed Tomography Follow-Up in Idiopathic Pulmonary Fibrosis: iPFBC Multicenter Pooled Comparison With Clinical and Functional Metrics”
Role: Principal Investigator
Funding: 7,500 euros
2. 2019 – Italian Foundation for Cancer Research (Associazione Italiana per la Ricerca sul Cancro, AIRC) Investigator Grant - IG 2019
Project title: “A Radio-Immuno-Genomic Approach to Identify Prognostic and Predictive Models for the Response to Immunotherapy in NSCLC” – PI: Prof. Nicola Sverzellati (Department of Medicine and Surgery, University of Parma, Parma, Italy)
Grant ID: 23606
Role: Experienced researcher
Funding: 1,119,000 euros
3. 2019 – Fondazione Cariparma
Project title: “Progetto Salute Parma (PSP): Prevenzione Primaria e Secondaria del Danno da Fumo” (Primary and Secondary Prevention (PSP) of Smoking Related Damage: Parma Project) – PI: Prof. Nicola Sverzellati (Department of Medicine and Surgery, University of Parma, Parma, Italy)

Grant ID: 0166/2019

Role: Scientific collaborator

Funding: 139,000 euros

4. 2020 – University of Parma “Bando straordinario di Ateneo per progetti di ricerca biomedica in ambito SARS-CoV-2 e COVID-19”
Project title: “Morbilità e mortalità da Covid-19 nel diabete mellito di tipo 2: possibile ruolo del macrofago e impatto di farmaci anti-diabete” – PI: Prof. Riccardo Bonadonna (Department of Medicine and Surgery, University of Parma, Parma, Italy)
Role: Scientific collaborator
5. 2020 – Swiss National Science Foundation (SNSF), National Research Programme (NRP) 78 entitled “COVID-19”
Project title: “AI-multi-omics-based Prognostic Stratification of COVID-19 Patients in Acute and Chronic State” – PI: Alexander Pollinger (Inselspital Bern, University of Bern, Bern, Switzerland)
Role: Scientific collaborator
Funding: 617,665 CHF
6. 2020 – Italian Ministry of Health, BANDO RICERCA FINALIZZATA 2019
Project title: “Model for Optimized Implementation of Early Lung Cancer Detection: Prospective Evaluation Of Preventive Lung HEalth (PEOPLHE)” – PI: Prof. Nicola Sverzellati (Department of Medicine and Surgery, University of Parma, Parma, Italy)
Role: Research team
Funding: 449,940 euro
7. 2022 – Italian Ministry of Health, BANDO RICERCA FINALIZZATA 2021 – Young Researchers Under 40
Project title: “A new diagnostic algorithm to non-invasively track fibrotic changes in myeloproliferative neoplasms based on C-C Chemokine Receptor 2 detection. From flow cytometry to the development of targeted Positron Emission Tomography molecular imaging. Pre-clinical studies and first in-human proof of concept” – PI: Prof. Elena Masselli (Department of Medicine and Surgery, University of Parma, Parma, Italy)
Role: Collaborator
Funding: 430,000 euro (GR-2021-12373308)
8. 2023 – Italian Ministry of Health, Piano Operativo Salute (POS), Traiettorie 3 (Medicina rigenerativa, predittiva e personalizzata)
Project title: “Integrative “Multi-Omics” And Functional Platform For The Complete Diagnostic Characterization Of Tumors: The Italian Tumor Chemogenomic Profiler (IT-TCP)” – PI: Prof. Giovanni Roti (Department of Medicine and Surgery, University of Parma, Parma, Italy)
Role: Investigator

Clinical Trials

Lung Cancer Screening by Low-Dose Computed Tomography

1. **MILD:** Multicentric Italian Lung Detection (ClinicalTrials.gov Identifier: NCT02837809)
2. **bioMILD:** Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study (ClinicalTrials.gov Identifier: NCT02247453)
3. **SMILE:** Screening and Multiple Intervention on Lung Epidemics (ClinicalTrials.gov Identifier: NCT03654105)

4. **PSP:** Progetto Salute Parma: Prevenzione Primaria e Secondaria del Danno da Fumo (Primary and Secondary Prevention (PSP) of Smoking Related Damage: Parma Project) (ClinicalTrials.gov Identifier: NCT04282694)
5. **PEOPLE:** Model for Optimized Implementation of Early Lung Cancer Detection: Prospective Evaluation Of Preventive Lung Health
6. **RISP:** Rete Italiana Screening Polmone
7. **4-IN THE LUNG RUN:** towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening
Funded in HORIZON 2020 (7,999,948.75 euro, Grant agreement ID: 848294)
url: <https://cordis.europa.eu/project/id/848294>

Thoracic Oncology

1. **EORTC (European Organisation for Research and Treatment of Cancer) Lung Cancer Group)**
 - a. **Study 1417:** “REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer”
(EudraCT number: 2014-003090-42)
 - b. **Study 1613:** “APPLE: Feasibility and activity of AZD9291 treatment on Positive PLasma T790M in EGFR mutant NSCLC patients”
(EudraCT number: 2016-001834-82)
 - c. **Study 1525:** “Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy – Nivothym”
(EudraCT number: 2015-005504-28)
2. **PARMA:** Progetto AIRC Ricerca Multiomica Avanzata (A Radio-Immuno-Genomic Approach to Identify Prognostic and Predictive Models for the Response to Immunotherapy in NSCLC) (ClinicalTrials.gov registration underway)

Oncoheamatology

1. ACE-CL-007: Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL (ClinicalTrials.gov Identifier: NCT02475681)
2. ACE-LY-308: A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma (ClinicalTrials.gov Identifier: NCT02972840)
3. 20130109: Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) (ClinicalTrials.gov Identifier: NCT02747043)
4. CC-5013-NHL-007: Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT) (ClinicalTrials.gov Identifier: NCT01938001)
5. GS-US-313-1580: Dose Optimization Study of Idelalisib in Follicular Lymphoma (ClinicalTrials.gov Identifier: NCT02536300)
6. B-MIND: A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (ClinicalTrials.gov Identifier: NCT02763319)
7. PCYC-1141-CA: Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (ClinicalTrials.gov Identifier: NCT02947347)

8. B3281006: A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) (ClinicalTrials.gov Identifier: NCT02213263)

Development Of Quantitative Imaging And Artificial Intelligence

1. 2013 – 2016 Pulmo3D and Airway Examiner, MeVis - Fraunhofer, Germany
2. 2013 – 2016 Parametric Response Map (PRM) for COPD phenotyping, Imbio - Minneapolis, MN
3. 2013 – present Quantitative Imaging Biomarkers Alliance (QIBA), Committee “QIBA Lung Density Biomarker” http://qibawiki.rsna.org/index.php/Lung_Density_Biomarker_Ctte
4. 2014 – 2018 CIRRUS Lung Screening, CAD system for detection and quantification of lung nodules – Radboud University Medical Center, Nijmegen, Netherlands
5. 2014 – 2015 OraMod European project, Multidisciplinary platform for comprehensive management of oral cancer “Imaging platform for quantitative analysis and standardized staging” – Imaging developers the Fraunhofer Institute for Computer Graphics IGD in Darmstadt (DE) and the University of Parma (IT).
Grant agreement ID: 611425
6. 2016 – 2019 BD2Decide project: A Prospective Observational Study for the Development and Validation of New Prognostic Models in Head and Neck Cancer Patients for Decision Support.
European Commission funded projects within the program “Horizon2020”, accessible within the Community Research and Development Information Service (CORDIS):
http://cordis.europa.eu/project/rcn/200298_en.html
H2020-PHC-2015-689715 BD2Decide
Grant agreement ID: 689715
7. 2017 – present Quantitative Imaging Biomarkers Alliance (QIBA), Committee “CT Small Lung Nodule Biomarker”
http://qibawiki.rsna.org/index.php/CT_Small_Lung_Nodule_Biomarker_Ctte
8. 2020 – present Institute for Diagnostic Accuracy (iDNA) awarded an EU project (4-in-the-lung-run) in the field of lung cancer screening and early diagnosis of smoking related lung disease and cardiovascular risk factors.

Membership Of Scientific Societies

1. Ordinary member of the Italian Society of Radiology (SIRM), Sections of Thoracic Imaging and Cardiovascular Imaging, since 2009
2. Elected delegate of “Young Radiologists” for the Regional Group of SIRM in Emilia-Romagna 2012-2013
3. Ordinary member of the European Society of Radiology since 2012
4. Ordinary member of the European Society of Thoracic Imaging (ESTI) since 2012
5. Junior member of the Radiology Society of North America (RSNA) since 2013
6. Ordinary member of Quantitative Imaging Biomarkers Alliance (QIBA) “COPD/Asthma” and “Lung Nodule assessment in CT screening” section at RSNA since 2013, and “CT Small Lung Nodule Biomarker Ctte” since 2018
7. Silver Under 35 member of European Respiratory Society (ERS) since 2014

8. European Organization for Research and Treatment of Cancer (EORTC – Lung Section) since 2015
9. Board member of the European Society of Thoracic Imaging (ESTI) since 2017
10. International Association for the Study of Lung Cancer (IASLC) since 2021
11. Elected delegate of “University Radiologists” for the Regional Group of SIRM in Emilia-Romagna 2025-2026 and 2027-2028

Membership Of International Scientific Committees

- 1) European Society of Thoracic Imaging (ESTI):
 - a. Member of the “Social Media Committee” (formerly “Electronic Media Committee”) (<http://esti.gr4fix.net/committee/>) 2017-2025
 - b. Lung cancer screening (LCS) certification project since 2019
URL: <https://www.myesti.org/lungcancerscreeningcertificationproject/>
 - c. European Society of Thoracic Imaging (ESTI) representative (aka: Subspecialty Society Delegate) in the European Society of Radiology (ESR) Research Committee since 2020
 - d. Member of the “Training and Educational Committee - LCS” in the Section
 - i. “Structured report” (<http://esti.gr4fix.net/committee/>) 2020-2023
 - ii. “CAD Workshops” (<http://www.myesti.org/committee/>) 2022-2025
- 2) European Society of Radiology (ESR): e-Learning committee “Chest Imaging” (role: Content lead) since 2018.

International Guidelines Committee

1. European Society of Radiology (ESR) and European Respiratory Society (ERS) white paper on Lung Cancer Screening. Chapters assigned:
 - a. Italian experience: Bonomo L, **Silva M**
 - b. Overdiagnosis: **Silva M**, Brodersen J, Gaga M, Bostantzoglou N, Revel MP
 - c. Biomarkers for lung cancer: **Silva M**, Blum T, Peled N, Gaga M
2. European Task Force: TF-2020-10 ERS/ESTI/ESR/ESTRO/ESTS Clinical Practice Guideline on the management of positive findings from low-dose CT screening for lung cancer

Editor For International Scientific Journals

1. European Journal of Radiology (ISSN: 0720-048X):
 - a. Section Editor of “Chest Imaging” since 2018 (impact factor 2.462)
 - b. Lead Editor of Section “Chest Imaging” since 2021 (impact factor 2.687)
URL: <https://www.ejradiology.com/content/edboard>
2. Tumori Journal (ISSN: 0300-8916): Section Editor of “Imaging Section” since 2019 (impact factor 1.304) – URL: <https://journals.sagepub.com/editorial-board/tmj>
3. British Journal of Radiology (ISSN: 0007-1285): Associate Editor of “Respiratory/Chest Diagnostics” since 2020 (impact factor 1.939) – URL: <https://www.birpublications.org/page/editorialboard/bjr>

Reviewer For International Authorities

1. Appointed peer reviewer by Cancer Research UK (<https://www.cancerresearchuk.org>), for the specific task of Early Detection Research Committee:
 - a. *Application Title: "ASCENT: Analysis of screen-detected lung cancers genomic traits"*
Application Reference: C9429/A28706
2. Interface Politikstudien Forschung Beratung GmbH (<https://www.interface-pol.ch/en>): appointed as "Italian expert" in International survey for planning of Lung Cancer Screening at population level in Switzerland

Reviewer For International Scientific Journals (selection)

1. "Respiration" (ISSN: 0025-7931) since 2013 (impact factor 2.651);
2. "COPD: Journal Of Chronic Obstructive Pulmonary Disease" (ISSN: 1541-2555) since 2013 (impact factor 2.673);
3. "BMC Musculoskeletal Disorders" (ISSN: 1471-2474) since 2014 (impact factor 1.941);
4. "Chest" (Print ISSN: 0012-3692; Online ISSN: 1931-3543) since 2014 (impact factor 5.94);
5. "Journal of Thoracic Imaging" (Print ISSN: 0883-5993; Online ISSN: 1536-0237) since 2014 (impact factor 1.723);
6. "Tumori Journal" (ISSN: 0300-8916) since 2015 (impact factor 1.071);
7. "Cancer Imaging" (ISSN: 1470-7330) since 2015 (impact factor 1.470);
8. "European Radiology" (Print ISSN: 0938-7994; Online ISSN: 1432-1084) since 2015 (impact factor 3.640);
9. "QJM: an International Journal of Medicine" (Print ISSN 1460-2725; Online ISSN 1460-2393) since 2015 (impact factor 2.634);
10. "Eurorad" brought by the European Society of Radiology (<https://www.eurorad.org/about-us>) since 2016.
11. "Acta Radiologica" (Print ISSN: 0284-1851; Online ISSN: 1600-0455) since 2016 (impact factor 2.009);
12. "BMC Pulmonary Medicine" (ISSN: 1471-2466) since 2017 (impact factor 2.329);
13. "European Journal of Radiology" (ISSN: 0720-048X) since 2017 (impact factor 2.462);
14. "Investigative Radiology" (ISSN: 0020-9996; Online ISSN: 1536-0210) since 2018 (impact factor 5.195);
15. "International Journal of Tuberculosis and Lung Disease (IJTLD)" (ISSN: 1027-3719; Online ISSN: 1815-7920) since 2018 (impact factor 2.468);
16. "British Medical Journal Open (BMJ Open)" (Online ISSN: 2044-6055) since 2018 (impact factor 2.413);
17. "European Respiratory Journal (ERJ)" (ISSN: 0903-1936; Online ISSN: 1399-3003) since 2018 (impact factor 12.242).
18. "Lung Cancer" (ISSN: 0169-5002) since 2019 (impact factor 4.486).
19. "British Journal of Radiology" (ISSN: 0007-1285) since 2019 (impact factor 2.050).
20. "Respiratory Medicine" (ISSN: 0954-6111) since 2019 (impact factor 3.230).
21. "Radiology" (ISSN: 0033-8419) since 2019 (impact factor 7.469).
22. "BMC Cancer Communications" (ISSN: 2523-3548) since 2019 (impact factor 3.644).
23. "Cancer epidemics" (ISSN: 1877-7821) since 2019 (impact factor 2.619).
24. "American Journal of Respiratory and Critical Care Medicine – AJRCCM" (ISSN: 1073-449X; Online ISSN: 1535-4970) since 2019 (impact factor: 16.494).
25. "Academic Radiology" (ISSN: 1878-4046) since 2019 (impact factor: 2.267).
26. "BMC Family Practice" (ISSN: 1471-2296) since 2019 (impact factor: 2.666).
27. "Respirator Research" (ISSN: 1465-993X) since 2019 (IF: 3.829).
28. "The Lancet Digital Health" (ISSN: 2589-7500) since 2020.
29. "BMC Infectious disease" (ISSN: 1471-2334) since 2020 (IF: 2.580).
30. "Annals of Oncology" (ISSN: 0923-7534) since 2020 (IF: 18.274).
31. "Cancers" (ISSN: 2072-6694) since 2021 (IF: 6.126)
32. "Respiratory Investigation" (ISSN: 2212-5345) since 2021 (IF: 1.64)
33. "The Lancet Oncology" (ISSN: 1470-2045 – eISSN: 1474-5488) since 2022 (IF: 41.316)
34. "The Lancet Respiratory Medicine" (ISSN: 2213-2600) since 2023 (IF: 102.642)
35. "JAMA Network Open" (ISSN: 2574-3805) since 2024 (IF: 13.8)

Editor Of Book

1. Cancer Dissemination Pathways (Series ISSN 2510-3474): The Thorax (1st ed. 2020 Edition) – Sverzellati N, **Silva M** Editors (Springer; eBook ISBN 978-3-030-27233-3; hardcover ISBN 978-3-030-27232-6) <https://www.springer.com/gp/book/9783030272326>

Author Of Book Chapters


1. Radiologia Medica collections 2010 – Corso Monotematico di radiologia Toracica
Authors: Sverzellati N, **Silva M**, Zompatori M. Chapter: BOOP and other interstitial lung diseases.
2. Patologia Toracica di Interesse Chirurgico - Monte Università Parma Editore 2011 – Parma – Italia – IMAGING DELLA PATOLOGIA NEOPLASTICA DEL TORACE
Authors: Di Lauro E, **Silva M**, Rossi C, Buttarelli L, Sverzellati N.
3. Atlas of Diffuse Lung Diseases – A Multidisciplinary Approach – Dalpiaz G, Cancellieri A Editors (Springer; ISBN 3319427504) – Chapters “Septal Disease” and “Nodular Disease”
Authors: Sverzellati N, **Silva M**
4. Bronchiectasis. The EMBARC Manual – Chalmers JD, Polverino E, Aliberti S Editors (Springer; ISBN 978-3-319-61451-9; ISBN e-book: 978-3-319-61452-6) <https://doi.org/10.1007/978-3-319-61452-6> – Chapter “Imaging of Bronchiectasis”
Authors: **Silva M**, Milanese G, Sverzellati N.
5. ESC Textbook of Cardiovascular Medicine 3rd edition (2019) – Luscher T, Camm J, Maurer G, Serruys P Editors (Oxford University Press) – Section 009: Chest radiography, Chapter “Focal abnormalities” Authors: Milanese G, **Silva M**, Sverzellati N.
6. Cancer Dissemination Pathways (Series ISSN 2510-3474): The Thorax (1st ed. 2020 Edition) – Sverzellati N, **Silva M** Editors (Springer; eBook ISBN 978-3-030-27233-3; hardcover ISBN 978-3-030-27232-6) <https://www.springer.com/gp/book/9783030272326>
 - a. Chapter 2: “Radiological Signs of Tumor Dissemination” – Authors: Beer L, Oberndorfer F, **Silva M**, Prosch H
 - b. Chapter 7: “Other Mediastinal Tumors” – Authors: Milone F, Taronna G, Gnetti L, **Silva M**
7. Grainger & Allison's Diagnostic Radiology 7th Edition (Elsevier; Hardcover ISBN 9780702075247; eBook ISBN 9780702075612– 9780702075629) – Adam A, Dixon A, Gillard J, Schaefer-Prokop CM Editors (2020) – Section “Chest and Cardiovascular System”, Chapter 9 “High-Resolution Computed Tomography of Interstitial and Occupational Lung Disease” – Authors **Silva M**, Sverzellati N
8. Malattie dell'apparato respiratorio – Pneumologia e Chirurgia Toracica 2nd Edition (ISBN-13 978-8855320542) – Loizzi M, Oliaro A. Ed. Minerva Medica (2021) – Chapter “La TC del torace nello screening del tumore polmonare”
Authors: Cardinale L, Stranieri G, Chiado' A, **Silva M**
9. Artificial Intelligence in Cardiothoracic Imaging (ISBN-13 978-3030920869) – De Cecco CN, van Assen M, Leiner T. Editors (2022) – Chapter “Artificial Intelligence-Based Evaluation of Patients with Interstitial Lung Disease”
Authors: **Silva M**, Milanese G, Ledda RE, Maddalo M, Sverzellati N.
10. Imaging in Geriatrics (ISBN 978-3-031-14877-4) – Guglielmi G, Maas M. Editors (2023) – Chapter “Airway Diseases in Geriatric Patients”
Authors: Balbi M, Ledda RE, Pamparino S, Milanese G, **Silva M**, Sverzellati N.

PubMed link: <https://www.ncbi.nlm.nih.gov/sites/myncbi/1nEPeKtjip95V/bibliography/47785154/public/?sort=date&direction=ascending>

h-index: 38 (source: Scopus <https://www.scopus.com/authid/detail.uri?authorId=56335785800>)

Documents: 168

Citations: 5,437



September 29, 2026

1. **Silva M**, Sverzellati N, Manna C, Negrini G, Marchianò A, Zompatori M, Rossi C, Pastorino U. Long-term surveillance of ground-glass nodules: evidence from the MILD trial. *J Thorac Oncol*. 2012 Oct;7(10):1541-6.
doi: 10.1097/JTO.0b013e3182641bba
2. De Filippo M, Castagna A, Steinbach SL, **Silva M**, Concari G, Pedrazzi G, Pogliacomì F, Sverzellati N, Petriccioli D, Vitale M, Ceccarelli F, Zompatori M, Rossi C. Reproducible Noninvasive Method for Evaluation of Glenoid Bone Loss by Multiplanar Reconstruction Curved Computed Tomographic Imaging Using a Cadaveric Model. *Arthroscopy*. 2013 Mar;29(3):471-7.
doi: 10.1016/j.arthro.2012.10.017
3. Sverzellati N, Randi G, Spagnolo P, Marchianò A, **Silva M**, Kuhnigk JM, La Vecchia C, Zompatori M, Pastorino U. Increased mean lung density: Another independent predictor of lung cancer? *Eur J Radiol*. 2013 Aug;82(8):1325-31.
doi: 10.1016/j.ejrad.2013.01.020
4. Sverzellati N, Colombi D, Randi G, Pavarani A, **Silva M**, Walsh SL, Pistolesi M, Alfieri V, Chetta A, Vaccarezza M, Vitale M, Pastorino U. Computed tomography measurement of rib cage morphometry in emphysema. *PLoS One*. 2013 Jul 31;8(7):e68546.
doi: 10.1371/journal.pone.0068546
5. Colombi D, Di Lauro E, **Silva M**, Manna C, Rossi C, De Filippo M, Zompatori M, Ruffini L, Sverzellati N. Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment. *Diagn Interv Radiol*. 2013 Nov-Dec;19(6):447-56.
doi: 10.5152/dir.2013.12021
6. Ariozi I, Paladini L, Gnetti L, **Silva M**, Colombi D, De Filippo M, Sverzellati N. Computed tomography-histologic correlations in lung cancer. *Pathologica* 2013 Dec; 105(6):329-36. Review.
PMID: 24730336
7. Litmanovich D, Hartwick K, **Silva M**, Bankier AA. Multidetector CT imaging in COPD: emphysema and airways assessment. *Radiol Clin North Am*. 2014 Jan;52(1):137-54.
doi:10.1016/j.rcl.2013.09.002

8. Shahrzad M, Le TSM, **Silva M**, Bankier AA, Eisenberg RL. Anterior mediastinal masses. *AJR Am J Roentgenol.* 2014 Aug;203(2):W128-38.
doi: 10.2214/AJR.13.11998
9. De Filippo M, Saba L, **Silva M**, Zagaria R, Concari G, Nizzoli R, Bozzetti C, Tiseo M, Ardizzoni A, Lipia S, Paladini I, Macarini L, Carrafiello G, Brunese L, Rotondo A, Rossi C. CT-guided biopsy of pulmonary nodule: is pulmonary hemorrhage a complication or an advantage? *Diagn Interv Radiol* 2014.
doi: 10.5152/dir.2014.14019
10. **Silva M**, Sabato M, Valentino M, Murrone S and Sverzellati N (2014) Unusual Findings of Langerhans Cell Histiocytosis in a Young Asymptomatic Patient: Case Report. *J Pulm Respir Med* 4:188.
doi: 10.4172/2161-105X.1000188 Not indexed in PubMed
11. Ariani A, Lumetti F, **Silva M**, Santilli D, Mozzani F, Delsante G, Sverzellati N. Systemic sclerosis interstitial lung disease evaluation: comparison between semiquantitative and quantitative CT assessments. *J Biol Regul Homeost Agents.* 2014 Jul-Sep;28(3):507-13.
PMID: 25316138
12. Nemec SF, Molinari F, Dufresne V, Gosset N, **Silva M**, Bankier AA. Comparison of Four Software Packages for CT Lung Volumetry in Healthy Individuals. *Eur Radiol.* 2015 Jun;25(6):1588-97.
doi: 10.1007/s00330-014-3557-3
13. Pastorino U, **Silva M**. Refining Strategies to Identify Populations to Be Screened for Lung Cancer. *Thoracic Surgery Clinics.* Published Online: February 17, 2015.
doi: 10.1016/j.thorsurg.2014.11.005
14. **Silva M**, Nunes H, Valeyre D, Sverzellati N. Imaging of Sarcoidosis. *Clin Rev Allergy Immunol.* 2015 Aug;49(1):45-53.
doi: 10.1007/s12016-015-8478-7
15. Ariani A, **Silva M**, Bravi E, Saracco M, Parisi S, De Gennaro F, Lumetti F, Idolazzi L, Seletti V, Caramaschi P, Benini C, Bodini FC, Scirè CA, Lucchini G, Santilli D, Mozzani F, Imberti D, Arrigoni E, Delsante G, Pellerito R, Fusaro E, Sverzellati N. Operator-independent Quantitative Chest Computed Tomography Versus Standard Assessment of Interstitial Lung Disease related to Systemic Sclerosis: a Multi-Centric Study. *Mod Rheumatol.* 2015 Sep;25(5):724-30.
doi: 10.3109/14397595.2015.1016200
16. DuBrock HM, Bankier AA, **Silva M**, Litmanovich DE, Curry MP, Washko GR. Pulmonary vessel cross-sectional area before and after liver transplantation: quantification with computed tomography. *Acad Radiol.* 2015 Jun;22(6):752-9.
doi: 10.1016/j.acra.2015.01.018
17. Colombi D, Manna C, Montermini I, Seletti V, Diciotti S, Tiseo M, Fontana E, De Filippo M, **Silva M**, Sverzellati N. Semiautomatic Analysis on CT scan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Reproducibility and Prognostic Significance of Uni-dimensional and Three-Dimensional Measurements. *J Thorac Imaging.* 2015 Sep;30(5):290-9.
doi: 10.1097/RTI.0000000000000145
18. De Filippo M, Saba L, Negrini G, **Silva M**, Pedrazzi G, Pogliacomì F, Castagna A. Inter-observer agreement of CT measurement of the glenoid bone surface by the CT Pico method: Comparison with laser in a cadaveric model. *Skeletal Radiol.* 2015 Oct;44(10):1491-7.
doi: 10.1007/s00256-015-2199-0
19. **Silva M**, Bankier AA, Centra F, Colombi D, Ampollini L, Carbognani P, Sverzellati N. Longitudinal Evolution of Incidentally Detected Solitary Pure Ground-Glass Nodules on CT: Relation to Clinical Metrics. *Diagn Interv Radiol (Ank).* 2015 Jul 3.
doi: 10.5152/dir.2015.14457
20. Walsh SLF, Calandriello L, Sverzellati N, Hansell DM on behalf of The UIP Observer Consort (Collaborators include **Silva M**). Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT.

Thorax 2015;0:1–7.

doi: 10.1136/thoraxjnl-2015-207252.

21. Lumetti F, Barone L, Alfieri C, **Silva M**, Serra V, Delsante G, Sverzellati N, Ariani A. Quality of Life and Functional Disability in Patients with Interstitial Lung Disease Related to Systemic Sclerosis. *Acta Biomed.* 2015 Sep 14;86(2):142-8.
PMID: 26422428
22. **Silva M**, Nemec S, Dufresne V, Occhipinti M, Heidinger B, Chamberlain R, Bankier AA. Normal Spectrum of Pulmonary Response Map: Distribution of Densitometric Classifications in Healthy Adult Volunteers. *Eur Radiol.* 2016 Sep;26(9):3063-70.
doi: 10.1007/s00330-015-4133-1
23. **Silva M**, Galeone C, Sverzellati N, Marchianò A, Calareso G, Sestini S, La Vecchia C, Sozzi G, Pelosi G, Pastorino U. Screening with Low Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer. *J Thor Oncol* Vol. 11 No. 2: 187-193.
doi:10.1016/j.jtho.2015.10.014.
24. Milanese G, **Silva M**, Sverzellati N. Lung volume reduction of pulmonary emphysema: the radiologist task. *Curr Opin Pulm Med.* 2016 Mar;22(2):179-86.
doi: 10.1097/MCP.0000000000000252.
25. Sverzellati N, **Silva M**, Calareso G, Galeone C, Marchianò A, Sestini S, Sozzi G, Pastorino U. Low-Dose Computed Tomography for Lung Cancer Screening: Comparison of Performance Between Annual and Biennial Screen. *Eur Radiol.* 2016 Nov;26(11):3821-3829. Epub 2016 Feb 11.
doi: 10.1007/s00330-016-4228-3
26. Ariani A, Aiello M, **Silva M**, Alfieri V, Bonati E, Lumetti F, Delsante G, Sverzellati N, Chetta A. Quantitative CT Indexes Are Significantly Related To Exercise Oxygen Desaturation in Interstitial Lung Disease Related to Systemic Sclerosis. *Clin Respir J.* 2016 Feb 22.
doi: 10.1111/crj.12451
27. Pastorino U, Boffi R, Marchianò A, Sestini S, Munarini E, Calareso G, Boeri M, Pelosi G, Sozzi G, **Silva M**, Sverzellati N, Galeone C, La Vecchia C, Ghirardi A, Corrao G. Stopping smoking reduces mortality in low-dose computed tomography (LDCT) screening volunteers. *J Thorac Oncol.* 2016 May;11(5):693-9.
doi: 10.1016/j.jtho.2016.02.011
28. Milanese G, Capretti G, Sverzellati N, **Silva M**. Lung cancer screening: are we ready now? *Shortness of Breath* Vol. 5 (No. 1) 2016 January-March.
doi: 10.11138/sob/2016.5.1.020 Not indexed in PubMed
29. Sestini S, Boeri M, Marchianò A, **Silva M**, Calareso G, Galeone C, Sozzi G, Pastorino U. Lung cancer screening in high-risk subjects: early detection with LDCT and risk stratification using miRNA-based blood test. *Epidemiol Prev.* 2016 Jan-Feb;40(1 Suppl 1):42-50.
doi: 10.19191/EP16.1S1.P042.029
30. Manna C, **Silva M**, Gazzani SE, Cobelli R. An uncommon cause of ascites: uroperitoneum from iatrogenic bladder fistula detected by CT urography. *BJR Case Rep* 2016; 2: 20150391.
doi: 10.1259/bjrcr.20150391. Not indexed in PubMed
31. Infante M, Sestini S, Galeone C, Marchianò A, Lutman FR, Angeli E, Calareso G, Pelosi G, Sozzi G, **Silva M**, Sverzellati N, Cavuto S, La Vecchia C, Santoro A, Aloisio M, Pastorino U. Lung cancer screening with low dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. *Eur J Cancer Prev.* 2017 Jul;26(4):324-329.
doi: 10.1097/CEJ.0000000000000264

32. Bozzetti F, Paladini I, Rabaiotti E, Franceschini A, Alfieri V, Visca D, Chetta A, Crisafulli E, **Silva M**, Pastorino U, Sverzellati N. Are interstitial lung abnormalities associated with COPD? A nested case-control study. *Int J Chron Obstruct Pulmon Dis*. 2016 May 26;11:1087-96.
doi: 10.2147/COPD.S103256.
33. **Silva M**, Zambrini EI, Chiari G, Montermini I, Manna C, Poli T, Lanfranco D, Sesenna E, Thai E, Sverzellati N. Pre-surgical Assessment of Mandibular Bone Invasion from Oral Cancer: Comparison Between Different Imaging Techniques and Relevance of Radiologist Expertise. *Radiol Med*. 2016 Sep;121(9):704-10.
doi: 10.1007/s11547-016-0654-1
34. Colombi D, Ehlers-Tenenbaum S, Palmowski K, Heussel CP, Sverzellati N, **Silva M**, Eichinger M, Kreuter M. Spontaneous Pneumomediastinum as a Potential Predictor of Mortality in Patients with Idiopathic Pulmonary Fibrosis. *Respiration*. 2016;92(1):25-33.
doi: 10.1159/000447430
35. Crisafulli E, Alfieri V, **Silva M**, Aiello M, Tzani P, Milanese G, Bertorelli G, Sverzellati N, Chetta A. Relationships Between Emphysema and Airways Metrics at High-resolution Computed Tomography (HRCT) and Ventilatory Response to Exercise in Mild to Moderate COPD Patients. *Respir Med*. 2016 Aug;117:207-14.
doi: 10.1016/j.rmed.2016.06.016
36. Pavarani A, Martini C, Gafà V, Bini P, **Silva M**, Ghetti C, Sverzellati N. Effect of iterative reconstruction on image quality of low-dose chest computed tomographic examinations. *Acta Biomed*. 2016 Sep 13;87(2):168-176.
PMID: 27648999
37. Landini N, Milanese G, Zambrini E, Ariozi I, Gnetti L, Carloni A, Nosenzo, **Silva M**, Sverzellati N. Computed Tomography-Histology Correlations of Unusual Lung Tumors. *Pathologica* 2016;108:110-119
PMID: 28195262
38. Rasciti E, Sverzellati N, **Silva M**, Casadei A, Attinà D, Palazzini M, Galiè N, Zompatori M. Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension. *Radiol Med*. 2017 Apr;122(4):257-264.
doi: 10.1007/s11547-016-0714-6
39. Ariani A, **Silva M**, Seletti V, Bravi E, Saracco M, Parisi S, De Gennaro F, Caramaschi P, Scirè C, Idolazzi L, Benini C, Bodini F, Lumetti F, Alfieri V, Bonati E, Lucchini G, Aiello M, Santilli D, Mozzani F, Imberti D, Michieletti E, Arrigoni E, Delsante G, Pellerito R, Fusaro E, Chetta AA, Sverzellati N. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis. *Rheumatology (Oxford)*. 2017 Feb 4.
doi: 10.1093/rheumatology/kew480.
40. **Silva M**, Pastorino U, Sverzellati N. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. *Clin Radiol*. 2017 May;72(5):389-400.
doi: 10.1016/j.crad.2016.12.021
41. Marchianò A, Cosentino M, Di Tolla G, Greco FG, **Silva M**, Sverzellati N, Fabbri A, Tamborini E, Lo Russo G, Mariani L, Lalli L, Pastorino U. FNA and CNB in the diagnosis of pulmonary lesions: a single-center experience on 665 patients, comparison between two periods. *Tumori*. 2017 Apr 28:0.
doi: 10.5301/tj.5000633
42. Manna C, **Silva M**, Poggesi S, Cobelli R, Rossi C, Sverzellati N. High-Pitch Dual-Source CT Angiography without ECG-gating for Imaging The Whole Aorta: Intra-individual Comparison with Standard Pitch Single-

Source Technique. Diagn Interv Radiol. 2017 Jul-Aug;23(4):293-299.
doi: 10.5152/dir.2017.16617

43. Milanese G, Sverzellati N, Pastorino U, **Silva M**. Adenocarcinoma in pure ground glass nodules: histological evidence of invasion and open debate on optimal management. J Thorac Dis 2017.
doi: 10.21037/jtd.2017.08.120
44. Pellegrino B, Facchinetti F, Bordi P, **Silva M**, Gnetti L, Tiseo M. Lung toxicity in non-small cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer. 2018 Mar;19(2):e151-e161.
doi: 10.1016/j.clcc.2017.10.008
45. **Silva M**, Milanese G, Seletti V, Ariani A, Sverzellati N. Pulmonary Quantitative CT Imaging in Focal and Diffuse Disease: Facing Clinical and Research Application. Br J Radiol. 2018 Feb;91(1083):20170644. doi: 10.1259/bjr.20170644
46. **Silva M**, Sverzellati N, Colombi D, Milanese G, La Vecchia C, Galeone C, Marchianò A, Pastorino U. Pleural plaques in lung cancer screening by low-dose computed tomography: prevalence, association with lung cancer and mortality. BMC Pulm Med. 2017 Nov 25;17(1):155.
doi: 10.1186/s12890-017-0506-3
47. Sverzellati N, Odone A, **Silva M**, Polverosi R, Florio C, Cortese G, Cardinale L, Addonizio G, Zompatori M, Dalpiaz G, Piciocchi S, Larici AR et al. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. Radiol Med. 2018 Apr;123(4):245-253.
doi: 10.1007/s11547-017-0835-6
48. Charbonnier JP, Chung K, Scholten ET, van Rikxoort EM, Jacobs C, Sverzellati N, **Silva M**, Pastorino U, van Ginneken B, Ciompi F. Automatic Vessel and Solid Core Segmentation in Pulmonary Subsolid Nodules. Sci Rep. 2018 Jan 12;8(1):646.
doi: 10.1038/s41598-017-19101-3
49. **Silva M**, Schaefer-Prokop CM, Jacobs C, Capretti G, Ciompi F, van Ginneken B, Pastorino U, Sverzellati N. Detection of Subsolid Nodules in Lung Cancer Screening: Complementary Sensitivity of Visual Reading and Computer-Aided Diagnosis. Invest Radiol. 2018 Aug;53(8):441-449.
doi: 10.1097/RLI.0000000000000464
50. Sverzellati N, **Silva M**. The matter of lung: quantification of vascular substance in asthma. Am J Respir Crit Care Med. 2018 Jun 8. doi: 10.1164/rccm.201804-0804ED.
51. **Silva M**, Pastorino U, Sverzellati N. Prospective randomised controlled trial: fixed 1-year screening interval group versus a tailored intervals group. Thorax. 2018 eLetter:
<http://thorax.bmj.com/content/early/2018/03/29/thoraxjnl-2017-211107.responses#prospective-randomised-controlled-trial-fixed-1-year-screening-interval-group-versus-a-tailored-intervals-group>
Not indexed in PubMed.
52. **Silva M**, Milanese G, Sverzellati N. Interstitial Lung Abnormalities: Definition of Prognostically Relevant Radiological Findings. Curr Opin Pulm Med. 2018 Sep;24(5):432-439.
doi: 10.1097/MCP.0000000000000497
53. **Silva M**, Prokop M, Jacobs C, Capretti G, Sverzellati N, Ciompi F, van Ginneken B, Schaefer-Prokop CM, Galeone C, Marchianò A, Pastorino U. Long-term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment. J Thorac Oncol. 2018 Oct;13(10):1454-1463.
doi: 10.1016/j.jtho.2018.06.013
54. Facchinetti F, Gnetti L, Balestra V, **Silva M**, Silini EM, Ventura L, Bordi P, Tiseo M. Sarcoid-like reaction mimicking disease progression in an ALK-positive NSCLC patient receiving lorlatinib. Invest

New Drugs 2019. 37(2):360-363
doi: 10.1007/s10637-018-0652-3

55. Walsh SLF, Calandriello L, **Silva M**, Sverzellati N. A Deep Learning Algorithm for Classifying Fibrotic Lung Disease on High-Resolution Computed Tomography. *Lancet Respir Med*. 2018 Nov;6(11):837-845.
doi: 10.1016/S2213-2600(18)30286-8
56. Nair A, Bartlett EC, Walsh SLF, Wells AU, Navani N, Hardavella G, Bhalla S, Calandriello L, Devaraj A, Goo JM, Klein JS, MacMahon H, Schaefer-Prokop C, Seo JB, Sverzellati N, Desai SR; Lung Nodule Evaluation Group (Collaborators included **Silva M**). Variable radiologic lung nodule evaluation leads to divergent management recommendations. *European Respiratory Journal* 2018. 52(6):1-12
doi: 10.1183/13993003.01359-2018
57. Milanese G, **Silva M**, Bruno L, Goldoni M, Benedetti G, Rossi E, Ferrari C, La Grutta L, Maffei E, Toia P, Bonadonna RC, Sverzellati N, Cademartiri F. Quantification of Epicardial Fat with cardiac CT and Association with Cardiovascular Risk Factors in Symptomatic Patients: from the ALTER-BIO (Alternative Cardiovascular Bio-Imaging Markers) Registry. *Diagn Interv Radiol* 2019; 25: 35-41.
doi: 10.5152/dir.2018.18037
58. Papapietro VR, Milanese G, Borghesi A, Sverzellati N, **Silva M**. Look Around Your Target: a New Approach to Early Diagnosis of Lung Cancer. *Ann Transl Med* 2018;6(Suppl 1):S77.
doi: 10.21037/atm.2018.10.56
59. Borghesi A, Michelini S, Nocivelli G, **Silva M**, Scrimieri A, Maroldi R, Farina D. Solid indeterminate pulmonary nodules ≤ 250 mm³: application of the updated Fleischner Society guidelines in clinical practice. *Radiology Research and Practice* 2019, Article ID 7218258
doi: 10.1155/2019/7218258
60. Ariani A, **Silva M**, Bravi E, Parisi S, Saracco M, De Gennaro F, Caimmi C, Girelli F, De Santis M, Volpe A, Lumetti F, Hax V, Bredemeier M, Alfieri V, Santilli D, Bodini FC, Mozzani F, Lucchini G, Seletti V, Bacchini E, Arrigoni E, Chakr R, Giuggioli D, Idolazzi L, Bertorelli G, Imberti D, Michieletti E, Paolazzi G, Fusaro E, Chetta A, Scirè CA, Sverzellati N. Overall mortality in Combined Pulmonary Fibrosis and Emphysema related to Systemic Sclerosis. *RMD Open* 2019;5:e000820.
doi: 10.1136/rmdopen-2018-000820
61. Pastorino U, **Silva M**, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, A Marchianò. Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial: New Confirmation of Lung Cancer Screening Efficacy. *Annals of Oncology* (Published: 01 April 2019)
doi: 10.1093/annonc/mdz117
62. Ledda RE, Milanese G, Gnetti L, Borghesi A, Sverzellati N, **Silva M**. Spread through air spaces in lung adenocarcinoma: is radiology reliable yet? *J Thorac Dis*. 2019 Mar;11(Suppl 3):S256-S261.
doi: 10.21037/jtd.2019.01.96
63. Milanese G, **Silva M**, Frauenfelder T, Eberhard M, Sabia F, Martini C, Marchianò A, Prokop M, Sverzellati N, Pastorino U. Comparison of Ultra-low Dose Chest CT Scanning Protocols for the Detection of Pulmonary Nodules: a Phantom Study. *Tumori*. 2019 May 1:300891619847271.
doi: 10.1177/0300891619847271
64. Pastorino U, Sverzellati N, Sestini S, **Silva M**, Sabia F, Boeri M, Cantarutti A, Sozzi G, Corrao G, Marchianò A. Ten-year Results of the MILD Trial Demonstrate the Safety and Efficacy of Biennial Lung Cancer Screening. *Eur J Cancer*. 2019 Sep;118:142-148.
doi: 10.1016/j.ejca.2019.06.009

65. Ravanelli M, Agazzi GM, Milanese G, Roca E, **Silva M**, Tiseo M, Rondi P, Baggi A, Ganeshan B, Muri M, Panni S, Botti C, Sverzellati N, Maroldi R, Berruti A, Farina D. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: a multicentre retrospective study. *Eur J Radiol.* 2019 Sep;118:251-256.
doi: 10.1016/j.ejrad.2019.07.019
66. **Silva M**, Milanese G, Pastorino U, Sverzellati N. Lung cancer screening: tell me more about post-test risk. *J Thorac Dis* 2019;11(9):3681-3688.
doi: 10.21037/jtd.2019.09.28
67. Heidinger BH, **Silva M**, De Margerie-Mellon C, VanderLaan P, Bankier AA. The Natural Course of Incidentally Detected, Small, Subsolid Lung Nodules – Is Follow-Up Needed Beyond Current Guideline Recommendations? *Transl Lung Cancer Res.* 2019 Dec;8(Suppl 4):S412-S417.
doi: 10.21037/tlcr.2019.11.05
68. **Silva M**, Milanese G, Cobelli R, Manna C, Rasciti E, Poggesi S, Sverzellati N. CT Angiography for Pulmonary Embolism in the Emergency Department: Optimized Protocol by 20 ml of High-Concentration Contrast Medium. *La radiologia medica*, 125(2), 137-144.
doi: 10.1007/s11547-019-01098-6
69. Guisado-Vasco P, **Silva M**, Duarte MA, Sambataro G, Bertolazzi C, Pavone M, Martín-Garrido I, Martín-Segarra O, Luque-Pinilla JM, Santilli D, Sambataro D, Torrisi SE, Vancheri A, Gutiérrez-México M, Mejía M, Palmucci S, Mozzani F, Rojas-Serrano J, Vancheri C, Sverzellati N Ariani A. Quantitative assessment of interstitial lung disease in Sjögren's syndrome. *Plos ONE* Volume 14, Issue 11, 2019, Article number e0224772.
doi: 10.1371/journal.pone.0224772
70. Sverzellati N, **Silva M**, Seletti V, Galeone C, Palmucci S, Piciucchi S, Vancheri C, Poletti V, Tomassetti S, Karwoski R, Bartholmai BJ. Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. *Eur Radiol.* 2020. Epub 2020 Jan 31.
doi: 10.1007/s00330-019-06619-5
71. Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, Čepická B, Comanescu A, Couraud S, Devaraj A, Jespersen V, Morozov S, Agmon IN, Peled N, Powell P, Prosch H, Ravara S, Rawlinson J, Revel MP, **Silva M**, Snoeckx A, van Ginneken B, van Meerbeeck JP, Vardavas C, von Stackelberg O, Gaga M, on behalf of the European Society of Radiology (ESR) and the European Respiratory Society (ERS). ESR-ERS joint position paper on Lung Cancer Screening. *Eur Respir J.* 2020 Feb;55(2). Print 2020 Feb. PubMed PMID: 32051182.
doi: 10.1183/13993003.00506-2019
72. Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, Čepická B, Comanescu A, Couraud S, Devaraj A, Jespersen V, Morozov S, Agmon IN, Peled N, Powell P, Prosch H, Ravara S, Rawlinson J, Revel MP, **Silva M**, Snoeckx A, van Ginneken B, van Meerbeeck JP, Vardavas C, von Stackelberg O, Gaga M, on behalf of the European Society of Radiology (ESR) and the European Respiratory Society (ERS). ESR-ERS joint position paper on Lung Cancer Screening. *Eur Radiol.* 2020 Feb 12; . [Epub ahead of print] PubMed PMID: 32052170.
doi: 10.1007/s00330-020-06727-7
73. Sverzellati N, Milanese G, Milone F, Balbi M, Ledda RE, **Silva M**. Integrated Radiologic Algorithm for COVID-19 Pandemic. *J Thorac Imaging.* 2020 Jul;35(4):228-233.
doi: 10.1097/RTI.0000000000000516.

74. Milanese G, **Silva M**, Ledda R, Goldoni M, Nayak SM, Bruno L, Rossi E, Maffei E, Cademartiri F, Sverzellati N. Validity of Epicardial Fat Volume as Biomarker of Coronary Artery Disease in Symptomatic Individuals: Results from the ALTER-BIO Registry. *International Journal of Cardiology*. Available online 13 April 2020. doi: 10.1016/j.ijcard.2020.04.031
75. Colombi D, Bodini FC, Petrini M, Maffi G, Morelli N, Milanese G, **Silva M**, Sverzellati N, Michieletti E. Visual and Software-based Quantification of Well Aerated Lung Obtained by Chest CT for Predictors in COVID-19 Interstitial Pneumonia. *Radiology*. 2020 Apr 17;201433. doi: 10.1148/radiol.2020201433
76. Revel MP, Parkar A, Prosch H, **Silva M**, Sverzellati N, Gleeso F, Brady AP; European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). COVID-19 patients and the Radiology department – advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). *Eur Radiol*. 2020 Sep;30(9):4903-4909. doi: 10.1007/s00330-020-06865-y
77. Mazzaschi G, Milanese G, Pagano P, Madeddu D, Falco A, Trentini F, Iorosso B, Gnetti L, Lagrasta C, Minari R, Ampollini L, **Silva M**, Sverzellati M, Tiseo M, Roti G. Integrated CT Imaging and Tissue Immune Features Disclose a Radio-Immune Signature with High Prognostic Impact on Surgically Resected NSCLC. *Lung Cancer*. 2020 Jun;144:30-39. doi: 10.1016/j.lungcan.2020.04.006
78. Mazzaschi G, Milanese G, Pagano P, Madeddu D, Gnetti L, Trentini F, Falco A, Frati C, Iorosso B, Lagrasta C, Minari R, Ampollini L, **Silva M**, Sverzellati N, Quaini F, Roti G, Tiseo M. Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer. *Data in Brief* Volume 31, August 2020, 105781 doi: 10.1016/j.dib.2020.105781
79. Scarlattei M, Baldari G, **Silva M**, Bola S, Sammartano A, Migliari S, Graziani T, Cidda C, Sverzellati N, Ruffini L. Unknown SARS-CoV-2 pneumonia detected by PET/CT in cancer patients. *Tumori Journal* published online 22 June 2020 doi: 10.1177/0300891620935983
80. Ruscitti F, Ravanetti F, Bertani V, Ragionieri L, Mecozzi L, Sverzellati N, **Silva M**, Ruffini L, Menozzi V, Civelli M, Villetti G, Stellari FF. Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography. *Front Pharmacol*. 2020 Jul 21;11:1117. doi: 10.3389/fphar.2020.01117
81. Colombi D, Villani GD, Maffi G, Risoli C, Bodini FC, Petrini M, Morelli N, Anselmi P, Milanese G, **Silva M**, Sverzellati N, Michieletti E. Qualitative and quantitative chest CT parameters as predictors of specific mortality in COVID-19 patients. *Emerg Radiol*. 2020 Dec;27(6):701-710. doi: 10.1007/s10140-020-01867-1
82. **Silva M**, Milanese G, Kauczor HU, Revel MP, Sverzellati N. Milestones towards lung cancer screening implementation. *Clin Radiol*. 2020 Aug 27;S0009-9260(20)30316-0. doi: 10.1016/j.crad.2020.07.028
83. Colombi D, Petrini M, Maffi G, Villani GD, Bodini FC, Morelli N, Milanese G, **Silva M**, Sverzellati N, Michieletti E. Comparison of admission chest computed tomography and lung ultrasound performance for diagnosis of COVID-19 pneumonia in populations with different disease prevalence. *Eur J Radiol Epub* 2020 Oct 8. doi: 10.1016/j.ejrad.2020.109344

84. Balbi M, Ristani A, Milanese G, **Silva M**, Ledda RE, Milone F, Sartorio C, Tringali G, Sverzellati N. The role of the radiologist in diagnosing the covid-19 infection. Parma experiences. Acta Bio-Medica De L'ateneo Parmense - ISSN:0392-4203 vol. 91 (2)
doi: 10.23750/abm.v91i2.9564
85. **Silva M**, Maddalo M, Leoni E, Giuliotti S, Milanese G, Ghetti C, Biasini E, Missale G, Sverzellati N. Integrated prognostication of intrahepatic cholangiocarcinoma by contrast enhanced computed tomography: the adjunct yield of radiomics. Abdom Radiol (NY). 2021 Oct;46(10):4689-4700. Epub 2021 Jun 24.
doi: 10.1007/s00261-021-03183-9
86. Ugolotti MC, Pedrazzini M, Silini EM, Missale G, **Silva M**, Franzini C, Palmieri G, Costi R, Montali F, Gnappi E, Terroni L, Colizzi E, Meschi M, Facchinetti F. Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient. Journal of Medical Virology 93(4), pp. 1940-1942
doi: 10.1002/jmv.26803
87. **Silva M**, Milanese G, Sestini S, Sabia F, Jacobs C, van Ginneken B, Prokop M, Schaefer-Prokop CM, Marchianò A, Sverzellati N, Pastorino U. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval. European Radiology 31(4), pp. 1956-1968.
doi: 10.1007/s00330-020-07275-w
88. Balbi M, Caroli A, Corsi A, Milanese G, Surace A, Di Marco F, Novelli L, **Silva M**, Lorini F, Cosentini R, Sverzellati N, Bonaffini PA, Sironi S. Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department. European Radiology 31(4), pp. 1999-2012
doi: 10.1007/s00330-020-07270-1
89. Luppi F, Sebastiani M, **Silva M**, Sverzellati N, Cavazza A, Salvarani C, Manfredi A. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clinical and Experimental Rheumatology 38(4), pp. S291-S300
PMID: 33095142
90. Carnevale A, **Silva M**, Maietti E, Milanese G, Saracco M, Parisi S, Bravi E, De Gennaro F, Arrigoni E, Bodini FC, Fusaro E, Scirè CA, Sverzellati N, Ariani A. Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests. Clinical Rheumatology 40(1), pp. 213-219.
doi: 10.1007/s10067-020-05375-y
91. **Silva M**, Ledda RE, Schiebler M, Balbi M, Milone F, Sverzellati N. Frequency of Typical and Ancillary Chest CT Findings in COVID-19 Infection. British Journal of Radiology 94(1118),20200716.
doi: 10.1259/bjr.20200716
92. Bartlett E, **Silva M**, Callister M, Devaraj A. False negative results in lung cancer screening - Evidence and Controversies. Journal of Thoracic Oncology 16(6), pp. 912-921.
doi: 10.1016/j.jtho.2021.01.1607
93. Sverzellati N, Ryerson C, Milanese G, Renzoni E, Volpi A, Spagnolo P, Bonella F, Comelli I, Manna C, Ciuni A, Sartorio C, Tringali G, **Silva M**, Michieletti E, Colombi D, Wells A. Chest radiography or computed tomography for suspected COVID-19 pneumonia? A comparative study in a simulated triage setting. European Respiratory Journal 58(3),2004188.
doi: 10.1183/13993003.04188-2020

94. Schreuder A, Jacobs C, Lessmann N, Broeders MJ, **Silva M**, Išgum I, de Jong PA, Sverzellati N, Prokop M, Pastorino U, Schaefer-Prokop CM, van Ginneken B. Combining pulmonary and cardiac computed tomography biomarkers for disease-specific risk modelling in lung cancer screening. *European Respiratory Journal* 58(3),2003386.
doi: 10.1183/13993003.03386-2020
95. Caminiti C, Maglietta G, Meschi T, Ticinesi A, **Silva M**, Sverzellati N. Effects of the Covid-19 epidemic on hospital admissions for Non-Communicable Diseases in a large Italian University-Hospital: a descriptive case-series study. *Journal of Clinical Medicine* 10(4),880, pp. 1-9
doi: 10.3390/jcm10040880
96. Avila R, Fain SB, Hatt C, Armato S, Mulshine JL, Gierada D, **Silva M**, Lynch DA, Hoffman EA, Ranallo F, Mayo JR, Yankelevitz D, San Jose Estepar R, Subramaniam R, Henschke C, Guimaraes A, Sullivan D. QIBA Guidance: Computed Tomography Imaging for COVID-19 Quantitative Imaging Applications. *Clinical Imaging* 77, pp. 151-157.
doi: 10.1016/j.clinimag.2021.02.017
97. Ariani, Sverzellati N, Milanese G, Becciolini A, **Silva M**. Using quantitative computed tomography to predict mortality in patients with interstitial lung disease related to systemic sclerosis: implications for personalized medicine. *Expert Review of Precision Medicine and Drug Development* 6(1), pp. 31-40
doi: 10.1080/23808993.2021.1858053
98. Tringali G, Milanese G, Ledda RE, Pastorino U, Sverzellati N, **Silva M**. Lung Cancer Screening: evidence, harms and opportunities for implementation. *RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren* 193(10), pp. 1153-1161.
doi: 10.1055/a-1382-8648.
99. Ma Q, Chen Y, Xiao F, Hao Y, Song Z, Zhang J, Okuda K, Um SW, **Silva M**, Shimada Y, Si C, Liang C. A Signature of Estimate-Stromal-Immune Score-Based Genes Associated with The Prognosis of Lung Adenocarcinoma. *Translational Lung Cancer Research* 10(3), pp. 1484-1500.
doi: 10.21037/tlcr-21-223
100. Ventura L, Gnetti L, Rossi M, Tiseo M, Silini EM, Sverzellati N, **Silva M**, Milanese G, Minari R, Cattadori S, Bocchialini G, Ampollini L, Carbognani P, Mozzoni P. The role of miRNA-221 and miRNA-126 in patients with Benign Metastasizing Leiomyoma of the lung: an overview with new interesting scenarios. *Molecular Biology Reports* 48(4), pp. 3485-3494.
doi: 10.1007/s11033-021-06322-z
101. Ledda RE, Milanese G, Cademartiri F, Maffei E, Benedetti G, Goldoni M, **Silva M**, Sverzellati N. Association of hepatic steatosis with epicardial fat volume and coronary artery disease in symptomatic patients. *Radiologia Medica* 126(5), pp. 652-660
doi: 10.1007/s11547-020-01321-9
102. Snoeckx A, Franck C, **Silva M**, Revel MP. Radiologist's role in lung cancer screening. The radiologist's role in lung cancer screening. *Translational Lung Cancer Research* 10(5), pp. 2356-2367.
doi: 10.21037/tlcr-20-924
103. **Silva M**, Milanese G, Ledda RE, Pastorino U, Sverzellati N. Screen-detected solid nodules: from nodule management to structured reporting. *Transl Lung Cancer Res.* 2021 May;10(5):2335-2346.
doi: 10.21037/tlcr-20-296
104. Ventura L, Carbognani P, Gnetti L, Rossi M, Tiseo M, Silini EM, Sverzellati N, **Silva M**, Succi M, Braggio C, Cattadori S, Bocchialini G, Balestra V, Rusca M, Ampollini L. Multiple primary malignancies involving lung

- cancer: a single-center experience. *Tumori* 107(3), pp. 196-203
doi: 10.1177/0300891620933678
105. Casartelli C, Perrone F, Balbi M, Alfieri V, Milanese G, Buti S, **Silva M**, Sverzellati N, Bersanelli M. Review on radiological evolution of COVID-19 pneumonia using computed tomography. *World J Radiol* 2021 September 28; 13(9): 294-306
doi: 10.4329/wjr.v13.i9.294
106. Colombi D, Bodini FC, Morelli N, **Silva M**, Milanese G, Cavanna L, Michieletti E. COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients. *Journal of Infection and Chemotherapy* 27(1), pp. 99-102
doi: 10.1016/j.jiac.2020.09.008
107. Sartorio C, Milanese G, Ledda RE, Tringali G, Balbi M, Milone F, Sverzellati N, **Silva M**. Diameter versus volumetry: A narrative review on current recommendations to measure and monitor screening detected lung nodules. *Shanghai Chest* 5(October),39
doi: 10.21037/shc-21-5
108. Buti S, Perrone F, Zielli T, Mazzaschi G, Casartelli C, Leonetti A, Milanese G, **Silva M**, Ledda RE, Musolino A, Pucci F, Bersanelli M, Tiseo M. Clinical Impact Of COVID-19 Outbreak On Cancer Patients: A Retrospective Study. *Clinical Medicine Insights: Oncology* 2021 Volume 15: 1–8
doi: 10.1177/117955492111043427
109. Jacobs C, Setio AAA, Scholten ET, Gerke PK, Bhattacharya H, Mohamed Hoesein F, Brink M, Ranschaert E, de Jong P, **Silva M**, Geurts B, Chung K, Schalekamp S, Meersschaert J, Devaraj A, Pinsky P, Lam S, van Ginneken B, Farahani K. Lung Cancer Detection in Screening CT Scans: Results from a Public Machine Learning Competition and an Observer Study. *Radiology: Artificial Intelligence* 3(6),e210027.
doi: 10.1148/ryai.2021210027
110. Martini K, Larici AR, Revel MP, Ghaye B, Sverzellati N, Parkar AP, Snoeckx A, Screatton N, Biederer J, Prosch H, **Silva M**, Gleeson F, Brady A, Frauenfelder T. COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR. *European Radiology* 32(4), pp. 2639-2649
doi: 10.1007/s00330-021-08317-7
111. Lancaster HL, Zheng S, Aleshina OO, Yu D, Chernina VY, Heuvelmans MA, Dorrius MD, Gratama JW, Morozov SP, Gombolevsky VA, **Silva M**, Yi J, Oudkerk M. Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification. *Lung Cancer* 2022 Jan 6;165:133-140
doi: 10.1016/j.lungcan.2022.01.002
112. **Silva M**, Milanese G, Ledda RE, Nayak SM, Pastorino U, Sverzellati N. European lung cancer screening: valuable trial evidence for optimal practice implementation. *British Journal of Radiology* 95(1133),20200260
doi: 10.1259/bjr.20200260
113. Trentini F, Mazzaschi G, Milanese G, Madeddu D, Gnetti L, Frati C, Lorusso B, Lagrasta C, Minari R, Ampollini L, Ledda RE, Pavone C, **Silva M**, Sverzellati N, Quaini F, Roti G, Tiseo M. A Validation of a Radiomic Approach to Decipher NSCLC Immune Microenvironment in Surgically Resected Patients. *Tumori* 108(1), pp. 86-92.
doi: 10.1177/03008916211000808
114. Ledda RE, Milanese G, Milone F, Balbi M, **Silva M**, Sverzellati N. Interstitial lung abnormalities: new insights between theory and clinical practice. *Insights into Imaging* 13(1),6.
doi: 10.1186/s13244-021-01141-z

115. Ledda RE*, **Silva M***, McMichael N, Sartorio C, Branchi C, Milanese G, Nayak SM, Sverzellati N. The diagnostic value of grey-scale inversion technique in chest radiography. *Radiologia Medica* 127(3), pp. 294-304.
doi: 10.1007/s11547-022-01453-0
116. Pastorino U, Boeri M, Sestini S, Sabia F, Milanese G, **Silva M**, Suatoni P, Verri C, Cantarutti A, Sverzellati N, Corrao G, Marchianò A, Sozzi G.
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. *Ann Oncol.* 2022 Jan 25;S0923-7534(22)00017-5
doi: 10.1016/j.annonc.2022.01.008
117. Huang LT, Cui M, **Silva M**, Wang JH, Wang YB. Expression Profiles of tRNA-Derived Fragments and Their Potential Roles in Lung Adenocarcinoma. *Ann Transl Med.* 2022 Feb;10(4):196.
doi: 10.21037/atm-22-119
118. Schreuder A, Jacobs C, Lessmann N, Broeders MJM, **Silva M**, Išgum I, de Jong PA, van den Heuvel MM, Sverzellati N, Prokop M, Pastorino U, Schaefer-Prokop CM, van Ginneken B. Scan-based competing death risk model for reevaluating lung cancer computed tomography screening eligibility. *European Respiratory Journal* 59(5),2101613
doi: 10.1183/13993003.01613-2021
119. **Silva M**, Picozzi G, Sverzellati N, Anglesio S, Bartolucci M, Cavigli E, Deliperi A, Falchini M, Falaschi F, Ghio D, Gollini P, Larici AR, Marchianò AV, Palmucci S, Preda L, Romei C, Tessa C, Rampinelli C, Mascalchi M. Low-dose CT for Lung Cancer Screening: Italian Position Paper. *Radiol Med.* 2022 Mar 20;1-17.
doi: 10.1007/s11547-022-01471-y
120. Walsh SLF, Mackintosh JA, Calandriello L, **Silva M**, Sverzellati N, Larici AR, Humphries SM, Lynch DA, Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Zappala C, Keir G, Cooper WA, Mahar AM, Ellis S, Wells AU, Corte TJ. Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-resolution Computed Tomography. *American journal of respiratory and critical care medicine* 206(7), pp. 883-891
doi: 10.1164/rccm.202112-2684OC
121. Humphries S, ; Mackintosh J, Jo H, Walsh S, Calandriello L, Glaspole I, Corte TJ, **Silva M**, Chapman S, Ellis S, Goh N, Grainge C, Hopkins P, Keir G, Moodley Y, Reynolds P, Walters H, Lynch D. Quantitative CT Predicts Patient Outcomes in IPF: Analysis from the Australian IPF Registry. *Respirology* 27(12), pp. 1045-1053
doi: 10.1111/resp.14333
122. Qian L, Zhou Y, Zeng W, Chen X, Ding Z, Shen Y, Qian Y, Tosi D, **Silva M**, Han Y, Fu X. A random forest algorithm predicting model combining intraoperative frozen section analysis and clinical features guides surgical strategy for peripheral solitary pulmonary nodules. *Transl Lung Cancer Res.* 2022 Jun;11(6):1132-1144
doi: 10.21037/tlcr-22-395
123. Mambrini M, Mecozzi L, Ferrini E, Leo L, Bernardi D, Grandi A, Sverzellati N, Ruffini L, **Silva M**, Stellari FF. The importance of routine quality control for reproducible pulmonary measurements by in vivo micro-CT. *Sci Rep.* 2022 Jun 11;12(1):9695
doi: 10.1038/s41598-022-13477-7
124. Sambataro D, Colaci M, Battisti S, Orlandi M, Cavagna L, Fazio G, Sverzellati N, **Silva M**, Malatino L, Ariani A. Feasibility, face and content validity of Quantitative Computed Tomography in Interstitial Lung Disease related to Connective Tissue Diseases. *Journal of Basic and Clinical Physiology and Pharmacology* 33(4), pp. 493-497
doi: 10.1515/jbcpp-2021-0110

125. Mulshine JL, Aldigé CR, Ambrose LF, Armato SG 3rd, Avila RS, Cham M, San Jose Estepar R, Fain SB, Gazourian L, Gierada DS, Hatt C, Henschke CI, Hoyos J, Lynch DA, McGlothlin AK, Oudkerk M, Pasquinelli M, Pinsky P, Pyenson B, Rizzo AA, Ross SM, Schmitz KH, **Silva M**, Okwuosa T, Washko G, Wisnivesky J, Yankelevitz DF, Zulueta JJ. Emphysema Detection in the Course of Lung Cancer Screening: Optimizing a Rare Opportunity to Impact Population Health. *Ann Am Thorac Soc*.
doi: 10.1513/AnnalsATS.202207-631PS
126. Milanese G, Mazzaschi G, Ledda RE, Balbi M, Lamorte S, Caminiti C, Colombi D, Tiseo M, **Silva M**, Sverzellati N. The radiological appearances of lung cancer treated with immunotherapy. *Br J Radiol*. 20210270.
doi: 10.1259/bjr.20210270
127. Nair A, Dyer DS, Heuvelmans MA, Mashar M, **Silva M**, Hammer MM. Contextualizing the Role of Volumetric Analysis in Pulmonary Nodule Assessment: AJR Expert Panel Narrative Review. *AJR Am J Roentgenol*. 2023 Mar;220(3):314-329.
doi: 10.2214/AJR.22.27830
128. Balbi M, Sabia F, Ledda RE, Milanese G, Ruggirello M, **Silva M**, Marchianò AV, Sverzellati N, Pastorino U. Automated coronary artery calcium and quantitative emphysema in lung cancer screening: association with mortality, lung cancer incidence, and airflow obstruction. *J Thorac Imaging*. 2023 Jan 20. Online ahead of print
doi: 10.1097/RTI.0000000000000698
129. Voigt W, Prosch H, **Silva M**. Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening-Can an Integrated Approach Overcome Current Challenges? *Cancers (Basel)*. 2023 Feb 14;15(4):1218.
doi: 10.3390/cancers15041218
130. Hunter B, Argyros C, Inglese M, Linton-Reid K, Pulzato I, Nicholson A, Kemp SV, Shah P, Molyneaux PL, McNamara C, Burn T, Guilhem E, Mestas Nuñez M, Hine J, Choraria A, Jordan S, Padley S, Ridge C, Robinson G, Robbie H, Barnett J, **Silva M**, Desai S, Aboagye EO, Devaraj A. Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis. *British Journal of Cancer*, 2023
doi: 10.1038/s41416-023-02480-y
131. Colombi D, Petrini M, Morelli N, **Silva M**, Milanese G, Sverzellati N, Michieletti E. Are Interstitial Lung Abnormalities a Prognostic Factor of Worse Outcome in COVID-19 Pneumonia? *J Thorac Imaging*. 2023 Feb 27. Online ahead of print.
doi: 10.1097/RTI.0000000000000704
132. Milanese G, Ledda RE, Sabia F, Ruggirello M, Sestini S, **Silva M**, Sverzellati N, Marchianò AV, Pastorino U. Ultra-low dose computed tomography protocols using spectral shaping for lung cancer screening: Comparison with low-dose for volumetric LungRADS classification. *Eur J Radiol*. 2023 Feb 28;161:110760. Online ahead of print.
doi: 10.1016/j.ejrad.2023.110760
133. Ventura L, Gnetti L, Milanese G, Rossi M, Leo L, Cattadori S, **Silva M**, Leonetti A, Minari R, Musini L, Pensato N, Illica Magrini F, Bocchialini G, Silini EM, Tiseo M, Sverzellati N, Carbognani P. Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights. *Arch Bronconeumol*. 2023 Jul;59(7):418-426.
doi: 10.1016/j.arbres.2023.03.015

134. Ghetti C, Ortenzia O, Bertolini M, Sceni G, Sverzellati N, **Silva M**, Maddalo M. Lung Dual Energy CT: impact of different technological solution on quantitative analysis. *Eur J Radiol* 2023 Jun;163:110812.
doi: 10.1016/j.ejrad.2023.110812
135. Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, **Silva M**, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbacher Y, Neven A, Peters S. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. *ESMO Open* 2023 Jun;8(3):101576.
doi: 10.1016/j.esmoop.2023.101576
136. M García Henao JA, Depotter AGA, Brown DV, Bajercius H, Todorova P, Saint-james H, Pahuddemortanges A, Barroso MC, He G, Yang J, You C, Staib L, Gange C, Ledda RE, Caminiti C, **Silva M**, Cortopassi I, Oliva IB, Dela Cruz C, Hautz W, Bonel H, Sverzellati N, Duncan J, Reyes M, Pöllinger A. A Multiclass Radiomics Method-Based WHO Severity Scale for Improving COVID-19 Patient Assessment and Disease Characterization From CT Scans. *Investigative radiology*, 2023, 58(12), pp. 882–893.
doi: 10.1097/RLI.0000000000001005
137. Venkadesh KV, Aleef TA, Scholten ET, Saghir Z, **Silva M**, Sverzellati N, Pastorino U, van Ginneken B, Prokop M, Jacobs C.
Prior CT Improves Deep Learning for Malignancy Risk Estimation of Screening-detected Pulmonary Nodules.
Radiology 2023 Aug;308(2):e223308.
doi: 10.1148/radiol.223308
138. Colombi D, Petrini M, Risoli C, Mangia A, Milanese G, **Silva M**, Franco C, Sverzellati N, Michieletti E. Quantitative CT at Follow-Up of COVID-19 Pneumonia: Relationship with Pulmonary Function Tests. *Diagnostics* 2023, 13(21), 3328
doi: 10.3390/diagnostics13213328
139. Behr C, Koffijberg H, IJzerman M, Kauczor HU, Revel MP, **Silva M**, von Stackelberg O, van Til J, Vliegenthart R.
Willingness to participate in combination screening for lung cancer, chronic obstructive pulmonary disease and cardiovascular disease in four European countries.
Eur Radiol, Published Online December 7, 2023
doi: 10.1007/s00330-023-10474-w
140. Desai SR, Sivarasan N, Johansson KA, George PM, Culver DA, Devaraj A, Lynch DA, Milne D, Renzoni E, Nunes H, Sverzellati N, Spagnolo P, Baughman Rp, Yadav R, Piciucchi S, Walsh SLF, Kouranos V, Wells AU, and the Sarcoid Delphi Group* (***Silva M** is part of the Sarcoid Delphi Group).
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study.
Lancet Respir Med 2023, Published Online December 14, 2023
doi: 10.1016/S2213-2600(23)00267-9
141. Milanese G, **Silva M**, Ledda RE, Iezzi E, Bortolotto C, Mauro LA, Valentini A, Reali L, Bottinelli OM, Ilardi A, Basile A, Palmucci S, Preda L, Sverzellati N; PEOPLE consortium.
Study rationale and design of the PEOPLE trial.
Radiol Med. 2024 Mar;129(3):411-419.
doi: 10.1007/s11547-024-01764-4
142. Balbi M, Mazzaschi G, Leo L, Moron Dalla Tor L, Milanese G, Marrocchio C, **Silva M**, Mura R, Favia P, Bocchialini G, Trentini F, Minari R, Ampollini L, Quaini F, Roti G, Tiseo M, Sverzellati N.
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Journal of Thoracic Imaging, 2024, 40(1), e0801.
doi: 10.1097/RTI.0000000000000801
143. Jiang B, Han D, van der Aalst CM, Lancaster HL, Vonder M, Gratama JWC, **Silva M**, Field JK, de Koning HJ, Heuvelmans MA, Oudkerk M.
Lung Cancer Volume Doubling Time by Computed Tomography: A Systematic Review and Meta-analysis.
European Journal of Cancer 2024, Online 26 September.
doi: 10.1016/j.ejca.2024.114339

144. Sverzellati N, Milanese G, Ryerson CJ, Hatabu H, Walsh SLF, Papapietro R, Gazzani SE, Bacchini E, Specchia F, Capretti G, Ledda RE, Milone F, **Silva M***, Iezzi E*.
Interstitial Lung Abnormalities on Unselected Abdominal and Thoracoabdominal CT Scans in 21 118 Patients.
Radiology, 2024, 313(2), e233374
doi: 10.1148/radiol.233374
145. Yang J, Henao JAG, Dvornek N, He J, Bower DV, Depotter A, Bajercius H, de Mortanges AP, You C, Gange C, Ledda RE, **Silva M**, Dela Cruz CS, Hautz W, Bonel HM, Reyes M, Staib LH, Poellinger A, Duncan JS.
Prior knowledge-guided vision-transformer-based unsupervised domain adaptation for intubation prediction in lung disease at one week.
Computerized Medical Imaging and Graphics, 2024, 118, 102442
doi: 10.1016/j.compmedimag.2024.10244
146. Walstra ANH, Lancaster HL, Heuvelmans MA, van der Aalst CM, Hubert J, Moldovanu D, Oudkerk S, Sytse F, Han D, Gratama JW, **Silva M**, de Koning HJ, Oudkerk M.
Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: impact on negative-misclassifications and clinical referral rate.
European Journal of Cancer, 2025, 216, 115214
doi: 10.1016/j.ejca.2024.115214
147. Yip R., Mulshine J.L., Oudkerk M., Field J., **Silva M.**, Yankelevitz D.F., Henschke C.I.
Current evidence of low-dose CT screening benefit
European Journal of Cancer, 2025
doi: 10.1016/j.ejca.2025.115570
148. Lancaster H.L., Jiang B., Davies M.P.A., Gratama J.W.C., **Silva M.**, Yi J., Heuvelmans M.A., de Bock G.H., Devaraj A., Field J.K., Oudkerk M.
Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction.
European Journal of Cancer, 2025
doi: 10.1016/j.ejca.2025.115324
149. Lancaster H.L., Walstra A.N.H., Myers K., Avila R.S., Gratama J.W.C., Heuvelmans M.A., Fain S.B., Clunie D.A., Kazerooni E.A., Giger M.L., Reeves A.P., Vogel-Claussen J., de Koning H., Yip R., Seijo L.M., Field J.K., Mulshine J.L., **Silva M.**, Yankelevitz D.F., Henschke C.I., Oudkerk M.
Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer.
European Journal of Cancer, 2025
doi: 10.1016/j.ejca.2025.115323
150. Mulshine J.L., Avila R.S., **Silva M.**, Aldige C., Blum T., Cham M., de Koning H.J., Fain S.B., Field J., Flores R., Giger M.L., Gipp I., Grannis F.W., Gratama J.W.C., Heaton C., Kazerooni E.A., Kelly K., Lancaster H.L., Montuenga L.M., Myers K.J., Naghavi M., Osarogiagbon R., Pastorino U., Pyenson B.S., Reeves A.P., Rizzo A., Ross S., Schneider V., Seijo L.M., Shaham D., Smith R., Taoli E., Tenhaaf, van der Aalst C.M., Viola L., Vogel-Claussen J., Walstra A.N.H., Wu N., Yang P.-C., Yip R., Oudkerk M., Henschke C.I., Yankelevitz D.F.
AI integrations with lung cancer screening: Considerations in developing AI in a public health setting.
European Journal of Cancer, 2025
doi: 10.1016/j.ejca.2025.115345
151. Mazzaschi G., Marrocchio C., Tor L.M.D., Leo L., Balbi M., Milanese G., Adebajo G.A.R., Lorusso B., Monica G., Pluchino M., Minari R., D'Agnelli S., Cardinale E., Perrone F., Bordini P., Leonetti A., Ledda R.E., **Silva M.**, Buti S., Roti G., Bettati S., Quaini F., Tiseo M., Sverzellati N.
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
Clinical Cancer Research, 2025.
doi: 10.1158/1078-0432.CCR-24-1926
152. Colombi D., Marvisi M., Ramponi S., Balzarini L., Mancini C., Milanese G., **Silva M.**, Sverzellati N., Uccelli M., Ferrozzì F.

Computer-Aided Evaluation of Interstitial Lung Diseases.

Diagnostics, 2025

doi: 10.3390/diagnostics15070943

153. Mulshine J.L., Pyenson B., Heaton C., Aldige C., Avila R.S., Blum T., Cham M., de Koning H.J., Fain S.B., Field J.K., Flores R., Giger M.L., Gipp I., Grannis F.W., Gratama J.W.C., Kazerooni E.A., Kelly K., Lancaster H.L., Montuenga L., Myers K.J., Naghavi M., Osarogiagbon R., Pastorino U., Reeves A.P., Rizzo A., Ross S., Schneider V., Seijo L.M., Shaham D., **Silva M.**, Smith R., Taioli E., ten Haaf K., van der Aalst C.M., Viola L., Vogel-Claussen J., Walstra A.N.H., Wu N., Yang P.-C., Yip R., Yankelevitz D.F., Henschke C.I., Oudkerk M. Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening. *European Journal of Cancer*, 2025
doi: 10.1016/j.ejca.2025.115264
154. **Silva M.**
The lung cancer screening marathon after baseline: evidence from incidence nodules. *European Radiology*, 2025
doi: 10.1007/s00330-025-11793-w
155. ESR Essentials: lung cancer screening with low-dose CT-practice recommendations by the European Society of Thoracic Imaging.
Revel MP, Biederer J, Nair A, **Silva M**, Jacobs C, Snoeckx A, Prokop M, Prosch H, Parkar AP, Frauenfelder T, Larici AR.
Eur Radiol. 2026 Mar;36(3):2064-2073.
doi: 10.1007/s00330-025-11910-9
156. Snoeckx A., **Silva M.**, Prosch H., Biederer J., Frauenfelder T., Gleeson F., Jacobs C., Kauczor H.-U., Parkar A.P., Schaefer-Prokop C., Prokop M., Revel M.-P.
Lung cancer screening with low-dose CT: definition of positive, indeterminate, and negative screen results. A nodule management recommendation from the European Society of Thoracic Imaging. *European Radiology*, 2025
doi: 10.1007/s00330-025-11648-4
157. Prokop M., Schaefer-Prokop C., Jacobs C., Snoeckx A., Biederer J., Frauenfelder T., Gleeson F., Kauczor H.-U., Parkar A.P., Vliegenthart R., Revel M.-P., **Silva M.**, Prosch H.
Aggressiveness-guided nodule management for lung cancer screening in Europe—justification for follow-up intervals and definition of growth. *European Radiology*, 2025
doi: 10.1007/s00330-025-11647-5
158. Jiang B, Lancaster HL, Davies MPA, Gratama JWC, **Silva M**, Han D, Yi J, van der Aalst CM, Devaraj A, Heuvelmans MA, Field JK, Oudkerk M.
AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation.
Eur J Cancer. 2026 Jan;232:116137. doi: 10.1016/j.ejca.2025.116137.
159. Automated artificial intelligence performance for longitudinal pulmonary nodule matching in lung cancer screening.
Jiang B, Lancaster HL, Davies MPA, Gratama JC, **Silva M**, Han D, Yi J, van der Aalst CM, Devaraj A, Heuvelmans MA, Field JK, Oudkerk M.
Eur Radiol. 2026 Aug 29.
doi: 10.1007/s00330-026-12825-9
160. Quantitative assessment of interstitial lung disease in rheumatoid arthritis.
Bertolazzi C, **Silva M**, Rojas-Serrano J, Ramos-Martínez E, Carnevale A, Sverzellati N, Gutierrez M, Alfaro-Rodriguez A, Ariani A.
Reumatol Clin (Engl Ed). 2026 May;22(5):502159
161. Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis.
Mackintosh JA, Walsh SLF, **Silva M**, Calandriello L, Humphries SM, Lynch DA, Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Zappala C, Keir G, Cooper WA, Mahar AM, Ellis S, Wells AU, Corte TJ.

- Respirology. 2026 May;31(5):521-529.
doi: 10.1002/resp.70196
162. Incidence and lung cancer probability of new nodules in the UK lung screening trial.
Jiang B, Lancaster HL, Davies MPA, Han D, Gratama JC, **Silva M**, van der Aalst CM, Devaraj A, Heuvelmans MA, Field JK, Oudkerk M.
Eur J Cancer. 2026 Jun 18;241:116779.
doi: 10.1016/j.ejca.2026.116779
163. Exploring the prevalence and clinical impact of carotid plaque burden by Doppler ultrasound in lung cancer screening participants with limited coronary artery calcification.
Mura R, Ledda RE, Moderato L, Leo L, Favia P, Zilioli C, Priore A, Maffucci FL, Gallone VI, Roberti C, Schirò S, **Silva M**, Sverzellati N, Milanese G.
Eur Radiol. 2026 Jul;36(7):5482-5491.
doi: 10.1007/s00330-026-12390-1
164. Negligible impact of perifissural nodules in an AI-first reader workflow from UK lung screening trial.
Jiang B, Han D, Cai J, Lancaster HL, Davies MPA, Walstra ANH, Gratama JC, **Silva M**, Yi J, van der Aalst CM, Heuvelmans MA, Field JK, Oudkerk M.
Eur Radiol. 2026 Aug;36(8):6209-6217.
doi: 10.1007/s00330-026-12444-4
165. Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.
Walstra ANH, Heuvelmans MA, Han D, Hubert J, van den Bosch I, Schmitz AMT, Oudkerk SF, van Leeuwen M, Nair A, **Silva M**, Gratama JWC, van der Aalst CM, de Koning HJ, Oudkerk M.
Eur J Cancer. 2026 Aug 26;244:116909.
doi: 10.1016/j.ejca.2026.116909
166. Smoking-Related Comorbidities Detected Through Low-Dose CT Imaging Lung Cancer Screening: Current Evidence and Future Directions.
Revel MP, Goo JM, Vliegenthart R, **Silva M**, Snoeckx A.
Chest. 2026 Sep;170(3):739-751.
doi: 10.1016/j.chest.2026.05.028
167. Benchmarking of AI and Radiologists for Indeterminate Lung Nodule Malignancy Risk Estimation at Screening CT: The LUNA25 Challenge.
Peeters D, Obreja B, Antonissen N, Saghir Z, Pastorino U, **Silva M**, de Bock GH, Gietema H, Gleeson F, Heuvelmans MA, Lam S, Litjens G, Hoesein FM, Schaefer-Prokop C, Scholten E, Snoeckx A, van der Heijden EHFM, Vliegenthart R, Prokop M, Jacobs C; LUNA25 Consortium; LUNA25 Consortium Members.
Radiol Artif Intell. 2026 Sep;8(5):e260179.
doi: 10.1148/ryai.260179
168. Quantitative computed tomography in interstitial lung disease related to ANCA-associated vasculitis: First insights from a mono-centric retrospective cohort.
Ariani A, **Silva M**, Rossi Gm, Delsante M, Becciolini A, Fiaccadori E, Vaglio A, Sverzellati N.
Rheumatology and Autoimmunity Open source preview, 2026, 6(1), pp. 57–59
doi: 10.1002/rai.2.70029

Congresses And Courses

Abstract Of Scientific Poster Presentation at National and International venues (since 2010)

1. Radiological Society of North America (RSNA)
2. European Society of Radiology (ESR)
3. European Society of Thoracic Imaging (ESTI)
4. Society of Thoracic Radiology (STR)
5. American Thoracic Society (ATS)
6. World Congress on Lung Cancer (WCLC)
7. International Association for Surgery of Lung Cancer (IASLC)
8. European Respiratory Society (ERS)
9. European Society of Cardiovascular Radiology (ESCR)
10. European Congress of Rheumatology EULAR
11. National Research Program 78 (Switzerland)
12. European Society of Medical Oncology (ESMO)
13. CHEST Congress

Abstract Of Oral Presentations at National and International venues (since 2011)

1. European Society of Radiology (ESR)
2. Systemic Sclerosis World Congress
3. Society of Thoracic radiology (STR)
4. Società Italiana di Radiologia Medica (SIRM)
5. American Thoracic Society
6. European Society of Thoracic Imaging (ESTI) (and joint meeting with the Fleischner Society)
7. World Congress of Thoracic Imaging (WCTI)
8. International Association for Surgery of Lung Cancer (IASLC)
9. European Society of Cardiovascular Radiology (ESCR)
10. European Society of Medical Oncology (ESMO)

Congresses/Courses AS FACULTY: Invited Speaker

Since year 2011, more than 100 invited talks at National and International Scientific venues, including:

1. HERMES National Summer School (European Respiratory Society, ERS)
2. International Thoracic Oncology Congress Dresden (ITOC 4)
3. Società Italiana di Radiologia Medica (SIRM)
4. Sezione di Radiologia Toracica, Società Italiana di Radiologia Medica (SIRM)
5. European Association of Cardio-Thoracic Surgery (EACTS)
6. Associazione Italiana Medici dell'Apparato Respiratorio
7. European Society of Thoracic Imaging (ESTI) (and joint meetings with the Fleischner Society)
8. Euroregional Conference on Thoracic Oncology
9. European Respiratory Society (ERS)
10. PneumoTrieste
11. Associazione Italiana Pneumologi Ospedalieri (AIPO)
12. World Association for Bronchology and Interventional Pulmonology and the International Bronchoesophagological Society (WCBIP/WCBE World Congress)
13. University of Florence
14. Congresso Nazionale della Pneumologia
15. HERMES National School (European Respiratory Society, ERS)
16. European Congress of Radiology (ECR)
17. AIR Meeting Italia
18. Deutscher Röntgenkongress
19. European Society of Cardiovascular Radiology (ESCR)
20. World Congress of Thoracic Imaging (WCTI)

21. Università di Brescia
22. Università di Palermo
23. International Association for the Study of Lung Cancer (IASLC)
24. World Congress on Lung Cancer (WCLC)
25. Universitätsspital Zürich (CH)
26. Netherlands Heart Days
27. Scandinavian MDCT course
28. Journées Francophones de Radiologie Diagnostique & Interventionnelle
29. Progetto SEGNO
30. Italian Network for Education in Residency Program
31. Pneumomedicina
32. Società Italiana di Endoscopia Toracica (SIET)
33. International Conference On Screening For Lung Cancer within the I-ELCAP Network
34. Associazione Italiana Tecnici di Radiologia in Radiodiagnostica e Tomografia Computerizzata (AITeRTC)
35. Alliance for Global Implementation of Lung and Cardiac Early Disease Detection (AGILEDxRx)
36. Prevent Cancer Foundation & American Lung Association

Congresses/Courses AS FACULTY: Moderator

Since year 2015, invited Moderator at several National and International Scientific venues, including:

1. European Society of Thoracic Imaging (ESTI) (and joint meeting with the Fleischner Society).
2. Sezione di Radiologia Toracica, Società Italiana di Radiologia Medica (SIRM)
3. European Congress of Radiology (ECR) Year 2017
4. World Congress of Thoracic Imaging (WCTI)
5. Associazione Italiana Pneumologi Ospedalieri (AIPO)
6. Società Italiana di Radiologia Medica (SIRM)
7. European Society of Cardiovascular Radiology (ESCR)
8. European Respiratory Society (ERS)
9. Netherlands Heart Days
10. Lung Cancer Screening Certification Program issued by European Society of Thoracic Imaging (ESTI).
11. International Association for the Study of Lung Cancer (IASLC)
12. World Congress of Lung Cancer (WCLC)
13. Alliance for Global Implementation of Lung and Cardiac Early Disease Detection (AGILEDxRx)

Congresses/Courses AS FACULTY: Scientific Committee

Year 2018

1. European Congress of Radiology (ECR) 2018, February 28-March 4, Vienna/Austria
Member of the **Scientific Subcommittee** "Chest".

Year 2019

2. European Congress of Radiology (ECR) 2019 February 27-March 3, Vienna/Austria
Member of the **Scientific Subcommittee** "Chest".

Year 2020

3. European Congress of Radiology (ECR) 2020 March 11-15, Vienna/Austria
Member of the **Scientific Subcommittee** "Chest".

Year 2021

4. International Association for the Study of Lung Cancer (IASLC) – World Congress of Lung Cancer 2021 (WCLC2021) September 8-14 – Online
Invited **Abstract Reviewer** (March 26, 2021)

Year 2022

5. International Association for the Study of Lung Cancer (IASLC) – World Congress of Lung Cancer 2022 (WCLC2022) August 6-9, Vienna/Austria
Chair for the “Early Detection and Screening” track

Year 2024

6. AGILE^{DxRx} Conference - Alliance for Global Implementation of Lung and Cardiac Early Disease Detection – May 9-11, Madrid/Spain
Planning Committee

Year 2025

7. AGILE^{DxRx} Conference - Alliance for Global Implementation of Lung and Cardiac Early Disease Detection – April 3-5, Bangkok/Thailand
Planning Committee
Education Director for the UEMS

Year 2026

1. AGILE^{DxRx} Conference - Alliance for Global Implementation of Lung and Cardiac Early Disease Detection – March 19-21, Gdansk/Poland
Planning Committee

Year 2027

1. AGILE^{DxRx} Conference - Alliance for Global Implementation of Lung and Cardiac Early Disease Detection – April 1-4, Vancouver/Canada
Planning Committee

International Regulatory Bodies – Policy Makers

Year 2025

1. European Cancer Organization (ECO) - [European Cancer Summit 2025](#)
Delegate of the European Society of Radiology (ESR) for the European Society of Thoracic Imaging (ESTI)

Updated September 2026

Mario Silva

Mario Silva

ATTACHMENTS

Attachment 1



BANDO D.D. 553/2021
SETTORE CONCORSUALE 06/I1
DIAGNOSTICA PER IMMAGINI, RADIOTERAPIA E NEURORADIOLOGIA

CANDIDATO: SILVA Mario - FASCIA: I

GIUDIZIO COLLEGIALE:

TITOLI	POSSESSO TITOLO (SI/NO)
a - Organizzazione o partecipazione come relatore a convegni di carattere scientifico in Italia o all'estero	Sì
b - Direzione o partecipazione alle attività di un gruppo di ricerca caratterizzato da collaborazioni a livello nazionale o internazionale	Sì
d - Responsabilità scientifica per progetti di ricerca internazionali e nazionali, ammessi al finanziamento sulla base di bandi competitivi che prevedano la revisione tra pari	No
e - Direzione o partecipazione a comitati editoriali di riviste, collane editoriali, enciclopedie e trattati di riconosciuto prestigio	Sì
f - Partecipazione al collegio dei docenti ovvero attribuzione di incarichi di insegnamento, nell'ambito di dottorati di ricerca accreditati dal Ministero	No
g - Formale attribuzione di incarichi di insegnamento o di ricerca (fellowship) presso qualificati atenei e istituti di ricerca esteri o sovranazionali	Sì
h - Conseguimento di premi e riconoscimenti per l'attività scientifica, inclusa l'affiliazione ad accademie di riconosciuto prestigio nel settore	Sì

VALUTAZIONE TITOLI:

Il Dott Mario Silva è ricercatore a tempo determinato L.240/10 tipo B Università degli Studi di PARMA

Dopo valutazione la Commissione attribuisce 5 titoli:

A perché confacente ai criteri stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016

B perché confacente ai criteri stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016

E perché confacente ai criteri stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016

G perché confacente ai criteri stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016

H perché confacente ai criteri stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016



Ministero dell'Università e della Ricerca

Mario Silva

Dopo valutazione la Commissione NON attribuisce 2 titoli

D perché NON confacente ai criteri stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016

F perché NON perché non dichiarato dal candidato.

GIUDIZIO:

Il Dott Mario Silva è ricercatore a tempo determinato L.240/10 tipo B Università degli Studi di PARMA Il candidato è valutato positivamente con riferimento al titolo 1 dell'Allegato A al D.M. 120/2016 poiché raggiunge 3/3 su 3 valori soglia dal D.M. 589/2018. Il candidato ha presentato N. 16 pubblicazioni scientifiche ex art. 7 DM 120/2016. Tenuto conto dei criteri di cui all'art. 4, del D.M. 120/2016, le pubblicazioni sono coerenti con le tematiche del settore concorsuale 06/I1 e con quelle interdisciplinari ad esso pertinenti, in quanto trattano Diagnostica per Immagini. La produzione scientifica del candidato risulta continua sotto il profilo temporale. La produzione scientifica risulta buona, sempre caratterizzata da rigore metodologico. La commissione attribuisce al candidato n. 5 titoli A, B, E, G ed H tra quelli stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016. Il titolo D non viene attribuito perché non in linea con i criteri stabiliti. Il titolo F non viene attribuito poiché non è stata presentata documentazione. Per le motivazioni di cui sopra, dopo analitico esame dei titoli e delle pubblicazioni ex art. 7 D.M. 120/2016, la Commissione all'unanimità ritiene che il candidato POSSIEDA la piena maturità scientifica richiesta per le funzioni di professore di I fascia

GIUDIZI INDIVIDUALI:

SERGIO BALDARI:

Il Dott Mario Silva è ricercatore a tempo determinato L.240/10 tipo B presso l'Università degli Studi di PARMA, SSD MED/36 - Diagnostica per immagini e radioterapia. Il candidato è valutato positivamente con riferimento al titolo 1 dell'Allegato A al D.M. 120/2016 poiché raggiunge 3/3 su 3 valori soglia dal D.M. 589/2018. Tenuto conto dei criteri di cui all'art. 4, del D.M. 120/2016, le pubblicazioni sono complessivamente coerenti con le tematiche del settore concorsuale 06/I1 e con quelle interdisciplinari ad esso pertinenti, in quanto trattano di Diagnostica per immagini. La produzione scientifica del candidato risulta continua sotto il profilo temporale. L'attività scientifica consta, in aggiunta ai 16 lavori presentati, di 121 ulteriori pubblicazioni. Le pubblicazioni presentate possono essere ritenute coerenti con il settore concorsuale e l'apporto individuale del candidato è chiaramente identificabile, risultando primo autore in 11 dei 16 lavori presentati, secondo autore in 4 e ultimo autore in uno. La produzione scientifica risulta continuativa e caratterizzata da rigore metodologico, e spunti innovativi e originali. La piena maturità scientifica del candidato è testimoniata dalla importanza delle tematiche scientifiche oggetto delle pubblicazioni e da risultati originali conseguiti nonché dalla collocazione di rilievo delle riviste. Le pubblicazioni sono di qualità elevata in relazione al settore concorsuale e alla fascia per la quale è stata richiesta l'abilitazione. Il candidato possiede n. n. 5 titoli A, B, E, G ed H tra quelli stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016: per il titolo A dichiara di aver partecipato in qualità di relatore a numerosi convegni di carattere nazionale e internazionale, su temi inerenti la patologia muscolo-scheletrica; per il titolo B è rilevabile documentazione delle collaborazioni con importanti gruppi di ricerca; per il titolo E fa parte dell' Editorial board di importanti riviste del settore della Diagnostica per immagini; per il titolo G risulta attestato "Research Fellow in Cardiothoracic Imaging; Department of Radiology, Beth Israel Deaconess Medical Center, Boston (MA); Harvard Medical School (HMS) per un periodo di un anno; per il titolo H ha ricevuto importanti riconoscimenti e premi in ambito di congressi nazionali ed internazionali. Il titolo D non può essere attribuito poiché quanto dichiarato/documentato non risponde ai criteri indicati dalla commissione. Il titolo F non può essere attribuito poiché il candidato non ne



Ministero dell'Università e della Ricerca

Mario Silva

dichiara il possesso. Per le motivazioni di cui sopra, dopo analitico esame dei titoli e delle pubblicazioni ex art. 7 D.M. 120/2016, ritengo che il candidato POSSIEDA la piena maturità scientifica richiesta per le funzioni di professore di I fascia, pertanto, sia da ritenersi IDONEO.

LORENZO LIVI:

Il Dott Mario Silva è ricercatore a tempo determinato L.240/10 tipo B Università degli Studi di PARMA

Il candidato è valutato positivamente con riferimento al titolo 1 dell'Allegato A al D.M. 120/2016 poiché raggiunge 3/3 su 3 valori soglia dal D.M. 589/2018. Il candidato ha presentato N. 16 pubblicazioni scientifiche ex art. 7 DM 120/2016. Tenuto conto dei criteri di cui all'art. 4, del D.M. 120/2016, le pubblicazioni sono coerenti con le tematiche del settore concorsuale 06/I1 e con quelle interdisciplinari ad esso pertinenti, in quanto trattano Diagnostica per Immagini. La produzione scientifica del candidato risulta continua sotto il profilo temporale. La produzione scientifica risulta buona, sempre caratterizzata da rigore metodologico. Attribuisco al candidato n. 5 titoli A, B, E, G ed H tra quelli stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016. Il titolo D non lo attribuisco perché il candidato non in linea con i criteri stabiliti. Il tritolo F perché non presentato. Per le motivazioni di cui sopra, dopo analitico esame dei titoli e delle pubblicazioni ex art. 7 D.M. 120/2016, ritengo che il candidato POSSIEDA la piena maturità scientifica richiesta per le funzioni di professore di I fascia

CARLO MASCIOCCHI:

Il Dott. Mario Silva è ricercatore a tempo tipo B nel SSD MED/36 presso Università degli Studi di Parma.

Il candidato è valutato positivamente con riferimento al titolo 1 dell'Allegato A al D.M. 120/2016 poiché raggiunge 3/3 su 3 valori soglia dal D.M. 589/2018.

Il Dott. Silva ha presentato N. 16 pubblicazioni scientifiche ex art. 7 DM 120/2016. Tenuto conto dei criteri di cui all'art. 4, del D.M. 120/2016, le pubblicazioni sono coerenti con le tematiche del settore concorsuale 06/I1 e con quelle interdisciplinari ad esso pertinenti. Esse sono principalmente incentrate su tematiche di diagnostica per immagini con una produzione scientifica continua sotto il profilo temporale.

L'apporto individuale del candidato è sempre chiaramente riconoscibile.

Le pubblicazioni sono di qualità elevata in relazione al settore concorsuale e alla fascia per la quale è stata richiesta l'abilitazione.

Il candidato possiede n. 5 titoli A, B, E, G ed H tra quelli stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016.

Il titolo D non viene attribuito in quanto non coerenti con i criteri indicati dalla commissione.

Il titolo F non è stato presentato dal candidato.

Per le motivazioni di cui sopra, dopo analitico esame dei titoli e delle pubblicazioni ex art. 7 D.M. 120/2016, ritengo che il candidato POSSIEDA la piena maturità scientifica richiesta per le funzioni di professore di I fascia, pertanto, sia IDONEO.

Letterio Salvatore POLITI:

Il Dott. Mario Silva è ricercatore a tempo tipo B nel SSD MED/36 presso Università degli Studi di Parma.

Il candidato è valutato positivamente con riferimento al titolo 1 dell'Allegato A al D.M. 120/2016 poiché raggiunge 3/3 su 3 valori soglia dal D.M. 589/2018.

Il candidato ha presentato N. 16 pubblicazioni scientifiche ex art. 7 DM 120/2016. Tenuto conto dei criteri di cui all'art. 4, del D.M. 120/2016, le pubblicazioni sono complessivamente coerenti con le tematiche del settore concorsuale 06/I1 e con quelle interdisciplinari ad esso pertinenti, principalmente incentrate su tematiche di diagnostica per immagini. La produzione scientifica del candidato risulta continua sotto il profilo temporale. L'apporto individuale del candidato è



Ministero dell'Università e della Ricerca

Mario Silva

sempre chiaramente riconoscibile. Le pubblicazioni sono di qualità elevata in relazione al settore concorsuale e alla fascia per la quale è stata richiesta l'abilitazione.

Al candidato vengono riconosciuti n. 5 titoli (A, B, E, G ed H) tra quelli stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016. Il titolo D non può essere attribuito poiché quanto dichiarato/documentato non risponde ai criteri indicati dalla commissione. Il titolo F non può essere attribuito poiché il candidato non ne dichiara il possesso.

Per le motivazioni di cui sopra, dopo analitico esame dei titoli e delle pubblicazioni ex art. 7 D.M. 120/2016, ritengo che il candidato POSSIEDA la piena maturità scientifica richiesta per le funzioni di professore di I fascia, pertanto, sia IDONEO.

GIUSEPPE RUBINI:

Il Dott Mario Silva è ricercatore a tempo determinato L.240/10 tipo B Università degli Studi di PARMA.

Il candidato è valutato positivamente con riferimento al titolo 1 dell'Allegato A al D.M. 120/2016 poiché raggiunge 3/3 su 3 valori soglia dal D.M. 589/2018.

Il candidato ha presentato N. 16 pubblicazioni scientifiche ex art. 7 DM 120/2016.

Tenuto conto dei criteri di cui all'art. 4, del D.M. 120/2016, le pubblicazioni sono complessivamente coerenti con le tematiche del settore concorsuale 06/11 e con quelle interdisciplinari ad esso pertinenti, in quanto trattano di Diagnostica per Immagini.

La produzione scientifica del candidato risulta continua sotto il profilo temporale.

L'apporto individuale del candidato è chiaramente riconoscibile. La produzione scientifica risulta continuativa e innovativa, sempre caratterizzata da rigore metodologico e ben collocata nel panorama scientifico nazionale e internazionale.

La piena maturità scientifica raggiunta dal candidato è attestata dalla importanza delle tematiche scientifiche affrontate e dal raggiungimento di risultati di rilevante qualità e originalità, tali da conferire una posizione ben riconosciuta nel panorama anche internazionale della ricerca.

Le pubblicazioni sono di qualità elevata in relazione al settore concorsuale e alla fascia per la quale è stata richiesta l'abilitazione.

Il candidato possiede n. n. 5 titoli A, B, E, G ed H tra quelli stabiliti dalla Commissione nella prima riunione ai sensi dall'art. 8, comma 1, del D.P.R. 95/2016. Il titolo D e F non vengono attribuiti in quanto non coerenti con i criteri indicati dalla commissione.

Per le motivazioni di cui sopra, dopo analitico esame dei titoli e delle pubblicazioni ex art. 7 D.M. 120/2016, ritengo che il candidato POSSIEDA la piena maturità scientifica richiesta per le funzioni di professore di I fascia, pertanto, sia IDONEO.

ABILITATO: Sì

VALIDO DAL 07/06/2022 AL 07/06/2032 (art. 16, comma 1, Legge 240/10)



Ministero dell'Università e della Ricerca

Mario Silva